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The human body is colonized by more than 100 trillion microbes which make up an 
essential part of the body and plays a significant role in health. We now know the over 
use and misuse of broad-spectrum antibiotics can disrupt this microbiome contributing to 
the onset of disease and runs the risk of promoting antibiotic resistance. With antibiotic 
research still on the decline, new strategies are greatly needed to combat emerging 
pathogens while maintaining a healthy microbiome. We therefore set out to present a 
novel species-selective antimicrobial drug discovery strategy.  
Disruption of the homeostasis within the oral cavity can trigger the onset of one of 
the most common bacterial infections, periodontal disease. Even though the oral cavity is 
one of the most diverse sites on the human body, the Gram-negative colonizer, 
Porphyromonas gingivalis has long been considered a key player in the initiation of 
periodontitis, suggesting the potential for novel narrow-spectrum therapeutics. By 
targeting key pathogens, it may be possible to treat periodontitis while allowing for the 
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recolonization of the beneficial, healthy flora. Therefore, we set out to use P. gingivalis 
and periodontal disease as a model for pathogen-specific antimicrobial drug discovery.  
In this study we present a unique approach to predict essential gene targets selective for 
the periodontal pathogen within the oral environment. Using our knowledge of metabolic 
networks and essential genes we identified a “druggable” essential target, meso-
diaminopimelate dehydrogenase, which is found in a limited number of species. This 
enzyme, meso-diaminopimelate dehydrogenase from P. gingivalis, was first expressed 
and purified, then characterized for enzymatic inhibitor screening studies. We then 
applied a computer-based drug discovery method, combining pharmacophore models, 
high-throughput virtual screening and molecular docking. Utilizing the ZINC database 
we virtually screened over 9 million small-molecules to identify several potential target-
specific inhibitors. Finally, we used target-based and whole-cell based biochemical 
screening to assess in vitro activity. We conclude that the establishment of this target and 
screening strategy provides a framework for the future development of new 
antimicrobials and drug discovery.  
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Introduction 
 
I. The Oral Microbiome  
The term “microbiome” was coined by Joshua Lederberg describing “the ecological community 
of commensal, symbiotic, and pathogenic microorganisms that literally share our body space” [1, 
2]. The start of the microbiome era resulted in the question of how commensal microorganisms 
contribute to human health and disease and sparked new areas of research. This directly led to 
the NIH-sponsored Human Microbiome Project. We now know that microbes outnumber our 
cells 10 to 1, making bacteria an important component of the human body. Through this project 
it was discovered the oral cavity is one of the most complex and diverse sites [3], containing up 
to 1000 phylotypes composed of viruses, protozoa, fungi, archaea and bacteria. However, since 
many oral bacteria have yet to be cultured, the number may be even higher [1, 4]. While the 
functional role of oral colonizers is not completely understood, studies indicate this area of the 
microbiome plays a role in maintaining oral health. For one, the occupation by commensal oral 
bacteria prevent the colonization of pathogens, a phenomenon known as colonization resistance 
[5]. Commensal bacteria occupy the niche, limiting the available space and preventing the 
establishment of foreign colonizers. As an indirect mechanism of colonization resistance, 
commensal oral colonizers can produce antagonistic substances against pathogenic species [4, 6]. 
For example, many streptococcal species can synthesize inhibitory substances that prevent 
colonization of other species. Streptococcus sanguinis produces hydrogen peroxide, which can 
inhibit the growth of methicillin-resistant Staphylococcus aureus [7] and Streptococcus mutans, a 
major contributor to dental caries [8]. Interestingly, studies also show the oral microbiome plays 
a functional role in systemic health. Inorganic nitrate obtained through the diet is reduced to 
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nitrite within the oral cavity, absorbed into the bloodstream and then converted to nitric oxide. 
This is beneficial, as metabolic studies show nitric oxide is important for maintaining 
cardiovascular health through improved mitochondrial function and reduced blood pressure [9]. 
Petersson et al. linked oral bacteria to this metabolic role by noting the use of antimicrobial 
mouthwash attenuated the nitrate reduction and abolished the associated decrease in blood 
pressure [10].  
Dental plaque. How is the complex oral microbiome established? The bacteria have the ability 
to colonize the hard and soft surfaces (e.g., teeth, surfaces of the tongue, and epithelium) of the 
oral cavity to form biofilms, more commonly known as dental plaque. Oral biofilms are 
polymicrobial 3D structures composed of proteins, polysaccharides, nucleic acids, salts and cells 
allowing for microbial interactions and cell-cell communication. It also provides the population 
with nutrients, protection from antibiotics and other environmental threats [11, 12]. The 
development of dental plaque is a systematic process occurring through five stages [12]. The first 
stage begins almost immediately following brushing. The tooth surface obtains a coating of 
glycoprotein deposits derived from saliva called the acquired pellicle. Through interactions with 
cell surface structures, the pellicle mediates the initial bacterial attachment. It can be 1-20 layers 
thick and within a clinically healthy cavity is composed of Gram-positive cocci, mainly of the 
streptococcus species [13, 14]. These early colonizers are aerobes or facultative anaerobes as 
they are able to tolerate the higher oxygen levels present [14, 15]. The second stage involves a 
stronger attachment of the bacteria to the tooth surface. Following initial attachment to the 
pellicle, weak, long-ranged interactions are formed that allows the bacteria to reverse the 
attachment to the pellicle and tooth surface. Stronger short-range, irreversible attachments 
between structures on the bacterial cell surface and the complementary receptors on the pellicle 
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are then formed [15]. The third step involves adhesion and aggregation of later colonizers to 
previously attached early colonizers.  Inter-bacterial adhesion-receptor interactions are initiated, 
resulting in the diversification of the biofilm [13], as well as generating synergistic and 
antagonistic interactions between species [15]. Fourth is the multiplication of the colonized 
bacteria; this step involves cell division of colonized bacteria and expansion of the biofilm into a 
complex 3D environment. Polymer composed of soluble and insoluble glucans is produced 
forming the extracellular matrix. This matrix provides structural integrity and retains nutrients 
within the biofilm. At this stage the biofilm is around 100-300 layers thick, generating an oxygen 
depleted environment that allows for an increase in the number of Gram-negative anaerobic 
bacteria [14, 16]. Last is active detachment. In response to environmental cues, the biofilm can 
detach from the surface, disperse and colonize at different locations [15].   
Periodontal disease. Typically, with proper oral hygiene, the oral microbiome exists in a 
beneficial or benign state. However, ecological changes in the oral cavity can alter the 
environment, shifting the dominant species from Gram-positive facultative anaerobes to Gram-
negative anaerobes. The resulting change in the environment can lead to a major health concern 
within the oral cavity known as periodontal disease [12]. Periodontal disease refers to a group of 
chronic inflammatory processes that affect the gingival tissue and surrounding tooth supporting 
structures [17]. Periodontal disease is a progressive disease that occurs in distinct stages. 
Gingivitis, the most common form, is the early non-destructive stage, which is composed of the 
initial, early and established lesion stages. It is reversible with proper cleaning and maintenance; 
however, without treatment gingivitis may progress into a more chronic infection. The advanced 
lesion stage marks the transition from gingivitis to periodontitis, the non-reversible destructive 
form. Periodontitis is characterized by severe inflammation, plaque calcification, bone 
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resorption, and tooth loss [18]. During the early lesion stages of the infection, within 2-10 days, 
accumulation of dental plaque triggers the host innate immune response where resident mast 
cells produce histamine causing the endothelium to release IL-8 [19, 20]. Additionally, 
macrophages recognize pathogen-associated molecular patterns (i.e., peptidoglycan, 
lipopolysaccharide and foreign DNA) through toll-like receptors (TLRs), triggering the uptake of 
the bacteria through phagocytosis and the release of cytokines such as IL-1β, IL-6 and TNF-α. 
The release of these pro-inflammatory cytokines cause vascular dilation of blood vessels, 
increasing permeability and blood flow. This also leads to the expression of adhesin molecules 
on the endothelium surface, aiding in the recruitment and sticking of polymorphonuclear 
neutrophils (PMNs) and activation of complement [21]. PMNs migrate to the epithelium and 
gingival crevice releasing more IL-8, amplifying inflammation. However, the PMNs are unable 
to phagocytose the bacteria, which are now associated within a thick biofilm. After 
approximately 2-3 weeks of biofilm accumulation, antigen-presenting cells begin to stimulate 
naïve T-cells. At this stage if T-cells have not eliminated the bacteria, an established lesion is set. 
This stage is defined by B-cell activation to plasma cells [20, 21]. Th2 cells activate B-cells and 
conversion of plasma cells leads to the secretion of antibodies. CD4+ T-cells continue to secrete 
cytokines contributing to collagen degradation and inflammation [21]. At this point, if the 
infection is not cleared, gingivitis progresses into periodontitis, corresponding to the advanced 
lesion stage and marked by severe collagen degradation. The formation of deep periodontal 
pockets allows for the migration of the biofilm, increased production of pro-inflammatory 
cytokines and continued tissue degradation [21]. Plasma cells are now the dominant immune 
cells. Continued T-cell response leads to the release of interleukins, TNF-α and prostaglandin 
E2, being mainly responsible for the alveolar bone destruction [22].  
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 Clinical Significance. The high prevalence of periodontal disease in developing and 
industrialized countries has made it a significant public health concern [14, 23]. The economic 
burden of the disease and subsequent treatment can be overwhelming. Oral related issues are the 
fourth most expensive disease, contributing up to 5-10% of health-care related costs [23, 24]. 
There are also corresponding psychological effects as the deterioration of the gum line and tooth 
loss can lead to embarrassment and low self-esteem [25, 26]. In addition, poor oral hygiene has 
been associated with systemic comorbidities. Brushing and invasive dental procedures allow 
bacteria to enter the bloodstream and disseminate to other sites, such as the brain, lungs and 
liver, linking periodontal disease to pregnancy complications, respiratory, cardiovascular and 
cerebrovascular diseases [23, 27, 28].  
Epidemiology. Periodontal diseases are some of the most common bacterial infections 
worldwide. It is estimated that approximately 82% of US children and 50% of adults display 
overt signs of gingivitis with gingival inflammation and bleeding. This percentage is higher for 
both children and adults in developing countries [29]. For the more severe form, it is estimated 
that around 46% or 64.7 million US adults 30 years and older have some stage of periodontitis. 
Unfortunately, this only increases with age. Chronic periodontitis is most prevalent in adults or 
seniors 65 years and older, with approximately 70.1% of the population afflicted [30]. 
Epidemiological studies have shown clear disparities in the estimated populations affected by 
periodontal disease. There are higher incidences of periodontitis in men than women (56.4% vs 
38.4%) and higher frequencies in individuals of African (59.1%) and Hispanic descent (63.5%) 
[30]. There is also a socioeconomic trend, with individuals with lower socioeconomic status 
more likely to present with periodontitis than those with a higher socioeconomic status [29, 31]. 
Specifically, approximately 65.4% of individuals in the US living below the federal poverty line 
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and 66.9% of individuals with less than a high school education have reported cases of 
periodontitis associated tooth loss.  
Risk Factors. A risk factor is defined as a variable that has been associated with 
increased risk of disease or infection [32] and studies show certain elements contribute to the 
development of periodontitis. Smoking, diabetes mellitus, age and stress are all strongly linked to 
the development of the disease [32, 33]. While these factors may not directly contribute to the 
disease, it is likely that the systemic changes (chronic inflammation and altered immune 
response) associated with these factors disrupt the oral ecosystem and contribute to the onset and 
prevalence of the disease. For example, patients with diabetes exhibit increased vascular 
permeability and impaired neutrophil migration contributing to their increased susceptibility for 
the disease [34]. However, it is important to note inherent non-modifiable factors such as genetic 
susceptibility and host response play a role in the progression of periodontal disease, as some 
people may exhibit one or more of the associated risk factors and never develop the disease [32].   
 It is widely accepted that the microbial population is a significant risk factor. Initially, it 
was believed periodontal disease was a result of the overwhelming presence of total bacteria in 
what was known as the non-specific plaque hypothesis [35-37]. However, in the 1970s, the 
specific plaque hypothesis was offered, stating that certain species played an etiological role in 
the onset. Evidence for this theory began with cariogenic bacteria. Loesche et al. noticed that 
antimicrobial therapy with kanamycin targeting oral streptococci reduced caries formation [35, 
38, 39]. Following this, Socranksy et al. offered supporting evidence by studying the complex 
poly-microbial environment based on the bacterial relationships corresponding to health and 
disease state. Socransky recognized that late colonizers Porphyromonas gingivalis, Treponema 
denticola and Tannerella forsythia (formerly Bacteroides forsythus) were isolated together from 
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diseased sites and expressed numerous virulence factors, corresponding to the effects of 
periodontitis. This bacteria group makes up what is still known as the ‘red complex’ [40, 41].  
 
II. Porphyromonas gingivalis 
One of the main pathogens within the oral cavity is Porphyromonas gingivalis. P. gingivalis is a 
Gram-negative non-motile, rod-shaped organism that belongs to the phylum Bacteroidetes and 
has long been considered a major causative agent in the onset and progression of periodontal 
disease [42, 43]. Identifying characteristics of the bacterium include anaerobic respiration, which 
is the degradation of amino acids for energy and the accumulation of hemin on the cell surface 
for the acquisition of iron, forming the characteristic black colonies on blood agar. P. gingivalis 
has been isolated from the oral cavity [18], the respiratory tract [44, 45], and from the vagina of 
women with bacterial vaginosis [46]. The genome of virulent P. gingivalis strain W83 was 
sequenced in 2003 by Nelson et al. revealing a 2.3 Mbp genome with 2,015 protein-coding genes 
[43]. P. gingivalis is a secondary colonizer thriving in nutrient rich areas with reduced oxygen 
levels, attaching to streptococci early colonizers [18, 47] as well as other late colonizers such as 
Fusobacterium nucleatum and Treponeam denticola [43, 48]. The bacterium is a part of the “red 
complex” as it is readily isolated from diseased sites and commonly found with other known oral 
pathogens [40, 49]. There is a positive correlation between an increase in periodontal pocket 
depth and P. gingivalis colonization [50]. Additionally, studies show there is improvement in 
periodontal health following the reduction of P. gingivalis [51]. Colonization and virulence of P. 
gingivalis is aided by the expression of protein adhesins, proteinases and hemagglutinins [18]. 
Virulence factors. A virulence factor is defined as a molecule produced by a pathogenic 
organism that contributes to the destructive nature of a disease and enables the pathogen to 
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survive within a specific host [52]. As previously mentioned, numerous studies have revealed a 
plethora of virulence factors that contribute to the colonization of P. gingivalis, the subversion of 
the host immune response and the destruction of the periodontal structures [18, 52].  
Gingipains. P. gingivalis possesses several proteases; however, the most studied belongs to a 
group of cell associated and secreted cysteine proteases known as gingipains. Gingipains 
contribute to a variety of virulent functions and have been classified based on their enzymatic 
specificity: arginine specific gingipains, Rgp and lysine specific gingipains, Kgp [18, 52]. One 
major purpose of gingipains is nutrient acquisition. Expression of Rgp and Kgp can induce 
epithelial cell death and tissue degradation that results in attainable nutrients for the bacteria 
within the environment [53]. It is also thought that P. gingivalis utilizes gingipains to break 
down transferrin and hemoglobin to obtain the iron necessary for survival [54]. This theory was 
supported by studying ginipain-deficient P. gingivalis cells. These mutants lost their 
characteristic black pigment on blood agar and their ability to bind hemoglobin [55, 56]. 
Gingipains also play a role in the deregulation of the host immune defense. Studies show that 
gingipains possess complement-like convertase activity by cleaving complement components 
and allowing for immune dysregulation [57, 58].  
Fimbriae. The fimbriae are long protein structures peritrichously arranged on the outer cell 
surface of the bacteria and facilitate adhesion to the surfaces of the oral cavity as well as other 
bacteria. Addition of purified monoclonal anti-fimbriae antibodies prevented binding and 
colonization of P. gingivalis to oral epithelial cells [59, 60] and strains of P. gingivalis with short 
or very few fimbriae were typically non-adherent to host cells [52]. The fimbriae may also play a 
role in periodontitis associated tissue destruction as immunization against P. gingivalis fimbriae 
in a rat model prevented tissue breakdown and characteristic periodontal destruction [52, 61].  
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Hemagglutinins. Hemagglutinins are microbial lectins or adhesins expressed on the bacterial 
cell surface and are essential for the initial attachment and establishment of infection. Binding is 
mediated through glycan receptors on host cells which may be facilitated by the fimbriae.  
Consequently, studies show antibodies against hemagglutinin HagB in P. gingivalis significantly 
reduced attachment to endothelial cells [62]. Hemagglutinins have long been associated with 
virulence as they may agglutinate erythrocytes [63] and sequence data shows that certain 
hemagglutinins can be co-expressed with genes containing proteolytic activity for the acquisition 
of iron [17]. The ability to block attachment and therefore colonization have led to new studies 
into vaccines targeting hemagglutinins as potential therapeutics [63].   
Lipopolysaccharide. Lipopolysaccharide (LPS) is a glycolipid found on the outer membrane 
of the bacterial cell surface. It is a potent immunostimulant, generating an array of 
immunological responses triggering inflammation and tissue destruction. P. gingivalis LPS has 
been shown to be endotoxic since the bacteria has the ability to release LPS in vesicles [64], 
which can then enter the host tissues [65, 66]. The interaction of LPS with the host tissues 
induces hallmark pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6. Recognition of 
LPS can directly stimulate osteoclasts leading to the release of IL-1β and TNF-α from various 
immune cells causing the hallmark signs of periodontitis: bone resorption and tissue destruction 
[17]. Toll-like receptor 4 (TLR4) is the major signal transducer for bacterial lipopolysaccharides; 
however, the P. gingivalis lipid A moiety of LPS has been described as atypical. It is less potent 
compared to other bacterial LPS. Furthermore, it is agonistic against TLR2, while being both 
antagonistic and agonistic for TLR4 [67]. This may be due to the differences in the chemical 
composition in response to environmental cues (i.e., fatty acid chain heterogeneity [68], changes 
in acylation patterns or phosphorylation of the lipid A moiety [17, 67]). The ability to alter the 
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LPS structure can be beneficial to P. gingivalis survival through manipulation of the innate 
immune response. This response suppresses inflammation and immune clearance early during 
infection, then later induces inflammation for nutrient acquisition. Furthermore, studies show 
that the atypical P. gingivalis LPS is able to down-regulate the stimulatory effect of other 
bacterial LPS by TLR4, which may stimulate E-selection on endothelial cells, thereby preventing 
neutrophil migration and evading clearance [17, 69].  
Keystone pathogen hypothesis. The ecological application of the term “keystone” refers to a 
species that is present in low numbers relative to the total population but still plays a major role 
in maintaining the integrity of the community [70]. Historically, P. gingivalis is known to be 
highly associated with the clinical signs of periodontal disease such as oral lesions and bone loss, 
while accounting for a small fraction of the oral population [71]. Evidence suggesting P. 
gingivalis could be a “keystone pathogen” began from a study when P. gingivalis colonized at 
less than 0.01% in specific-pathogen free mice, induced destructive periodontitis. These effects 
were not observed in germ-free mice, indicating the onset of periodontal disease is related to 
changes in the microbial population induced by P. gingivalis [58]. This was further characterized 
by showing that the colonization of P. gingivalis selectively modified the host immune response 
leading to the disruption of the normal host microbiota [58]. Following colonization, P. 
gingivalis prevented epithelial cell secretion of IL-8, a chemoattractant for PMN that hindered 
neutrophil migration and attenuated the first line of immune defense [58, 72, 73]. Interestingly, 
this colonization also prevented complement activation, which facilitated in the survival of the 
periodontal pathogen, the increase in commensal bacterial load and induction of bone loss [58]. 
P. gingivalis cleaves the complement component C5 into C5a by gingipains [74] and the 
downstream effect of C5aR in conjunction with TLR2 stimulated by the pathogen-associated 
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LPS leads to a break within the signaling pathway preventing phagocytosis. This interaction is 
important to the dysregulation as gingipain-deficient strains of P. gingivalis show no changes in 
the oral micro-environment maintaining the bacterial balance [75, 76]. The interaction with 
TLR2 prevents the production of IL-12 cytokines, but increases proinflammatory mediators IL-
1β, IL-6 and TNF-α. This selective immunosuppressive mechanism aids P. gingivalis in resisting 
immune clearance while allowing for cytokines that are involved in bone resorption and tissue 
degradation to generate a nutrient rich, inflamed site [77]. The now altered oral environment may 
select for asaccharolytic organisms such as P. gingivalis since they are able to utilize available 
nutrients. In addition, the degeneration of alveolar bone provides new niches for pathogenic 
species. P. gingivalis also alters macrophage function. The bacteria interact with lipid rafts on 
the macrophage cell surface, allowing for a close interaction between FimA and CXCR4 and 
TLR2 on the macrophage cell surface. Crosstalk between the two receptors increases cAMP 
levels and inhibits the oxidative burst facilitated clearance by macrophages [45, 78].  
P. gingivalis as a potential target. Corresponding to the evidence of being a keystone pathogen, 
studies of immunization directed specifically against P. gingivalis have shown promise as a 
therapeutic strategy for periodontal disease. Mice immunized with purified P. gingivalis capsular 
polysaccharide developed high IgM and IgG serum titers, which elicited protection against P. 
gingivalis-induced bone loss [79]. Several studies have shown success in targeting outer-
membrane proteins (OMP) [80-83]. For instance, P. gingivalis-challenged mice exhibited 
decreased oral lesions when immunized against recombinant forms of an OMP-like protein [83]. 
Another study using a rat model examining immunization against the adhesin motif of 
hemagglutinin HagB showed a reduction in periodontitis associated bone loss [62, 84, 85]. A 
study in non-human primates, vaccinating against an outer membrane protein or a lysine 
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gingipain protease complex significantly reduced alveolar bone loss and decreased P. gingivalis 
cell viability [86, 87]. Finally, a human clinical study providing repeated applications of 
monoclonal antibodies specific to a P. gingivalis protease complex prevented recolonization of 
the pathogen for approximately 9 months, leading to significant improvement of oral health [84, 
88]. 
 
III. Antibiotics 
 
Antibiotics or antimicrobials are some of the most commonly prescribed medications worldwide 
[89] and describe any molecule that targets essential functions (e.g., DNA replication, protein 
synthesis, cell wall synthesis and cell membrane) to kill or stop the growth of infectious 
organisms [90-92]. Around 1930, the modern “golden age” of antimicrobial research began, 
representing one of the greatest medical achievements [93, 94]. Beginning in the early 1900s, 
Paul Ehrlich hypothesized the possibility of selectively targeting pathogenic microbes while 
sparing the host [90]. However, it wasn’t until 1928 that the theory became a reality when 
Alexander Flemming made a fortuitous discovery that resulted in the wide spread use of 
penicillin [90]. Spanning a 40-year period, researchers and pharmaceutical companies examined 
microbial and fungal metabolites for naturally occurring antibiotics leading to discovery of the 
major antibiotic class scaffolds: cephalosporins, penicillins, quinolones and macrolides, still used 
today [90, 95]. During this period, steady progress was made with improvements in the form of 
second and third generation synthetic derivatives, resulting in various β-lactams, sulfonamides, 
and aminoglycosides then tetracyclines, macrolides and glycopeptides [90, 95, 96]. By the 
1980s, development began to slow. The ideal natural sources had been exhausted, leading to a 
drop in progress and interest. Any newly designed antimicrobials, by that point, were chemical 
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modifications of common core scaffolds and targets, incrementally improving potency and 
efficacy. A few novel compounds were identified however, but none made it to market until 
years later. This included linezolid, an oxazolidinone class discovered in 1978, approved in 
2000, daptomycin, a lipopeptide antibiotic discovered in 1986, approved in 2003 and 
retapamulin, a pleuromutilin approved in 2007 [93]. 
Antibiotic resistance. The discovery of antimicrobials brought about a significant turn in the 
constant battle against bacterial infections, increasing both the quality and span of the average 
life [92, 97]. However, the rise of antibiotic resistance has threatened to diminish this feat, 
rendering many antibiotics ineffective. Resistance is defined as a change in the bacteria’s level of 
susceptibility to a drug, in regards to the normal population. This change can occur through 
mutations or the acquirement of heterologous genes coding for resistance by means of horizontal 
gene transfer [98]. Once expressed, the acquired gene provides a selective advantage for the 
pathogen when exposed to antibiotics leading to the spread and dominance of resistant strains 
within the population [90]. Mechanistically, bacterial resistance can occur in four ways. First, the 
modification of the drug target. For example, resistance to the glycopeptide vancomycin is 
mediated through the acquired vanA gene. VanA codes for an enzyme that synthesizes a 
peptidoglycan with one less hydrogen bond, decreasing vancomycin’s affinity by 1000-fold. 
Second is the inactivation of the drug. Aminoglycoside antibiotics such as kanamycin are left 
ineffective due to the production of aminoglycoside-modifying enzymes that covalently attach a 
moiety (e.g., phosphate, acetyl or adenyl) to a key functional group of the antibiotic. This 
modification is a steric hinderance to binding of the ribosome. The third method is 
impermeability, such as the down-regulation of porins. Fourth, resistance can occur through the 
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explusion of the drug. Streptogramin resistance by E. faecalis is partially due to the presence of 
ABC transporter Lsa, which removes the drug and prevents access to the target [98-101].  
Antibiotic resistance not only increases healthcare related cost forcing the use of more 
expensive drugs and prolonging treatment times, but it is a significant threat to our morbidity and 
mortality [98]. By 2004, it was documented that approximately 70% of pathogenic bacteria were 
resistant to at least one antibiotic. This has resulted in at least two million illnesses and 23,000 
deaths, adding an additional $20 billion to healthcare cost [102]. Rising resistance in 
Staphylococcus aureus is one well-known example. This Gram-positive pathogen 
asymptomatically colonizes 30% of the population and is known to be extremely adaptable 
against antibiotic pressure [103, 104]. By the beginning of 1950, shortly following the 
introduction of penicillin into clinical practice, a large proportion of hospital staphylococcal 
infections were already penicillin-resistant [105]. Initially only found throughout hospitals, 
within a few years, penicillin-resistant strains began causing community acquired infections. 
This led to the use of methicillin as the first drug of choice. Nevertheless, by 1961, cases of 
methicillin-resistant Staphylococcus aureus (MRSA) were on the rise in the United Kingdom and 
by the 1980s, MRSA infections were widespread within the United States [104, 106, 107]. From 
that point, vancomycin became the last line of effective antibiotics. Again, antibiotic pressure led 
to the emergence of vancomycin-intermediate S. aureus strains (VISA) and by 2002, cases of 
strains displaying complete resistance or vancomycin-resistant S. aureus strains (VRSA) were 
found within the US [104]. In 2006 the CDC reported antibiotic resistant S. aureus infections 
such as pneumonia, sepsis and necrotizing fasciitis, resulted in approximately 19,000 deaths [95, 
102]. Re-emerging pathogens such as Mycobacterium tuberculosis, the etiological agent for 
tuberculosis (TB), add another layer of concern. While TB infections were once on the decline, 
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in 2013 there were around 480,000 new multi-drug resistant TB (MDR-TB) cases and 100 
countries reporting cases of extensively-drug resistant TB (XDR-TB) strains resistant to first-line 
and second-line therapies [92, 108, 109]. XDR-TB is extremely difficult to treat, requiring at 
least two years of antimicrobial therapy. Additionally, effective therapy typically relies on 
antibiotic drugs that are expensive, toxic and potentially lethal [95].  
Antibiotics and the microbiome. Humans are colonized with over 100 trillion bacteria, which 
led to a symbiotic host-microbe relationship [110]. The microbiome plays important functional 
roles, from establishing our immune system after birth [111, 112] to influencing how our brains 
process information [113, 114]. Since the Human Microbiome Project, there has been growing 
interest in the healthy human microbiome and how changes in it relate to the development of 
disease [3, 110, 115, 116]. Therefore, it is not surprising that disruption in that normal microbiota 
(as a result of the overuse or misuse of broad-spectrum antibiotics) has been linked to a multitude 
of systemic diseases. Reoccurring Clostridium difficile infection is a distinctive case of changes 
in the microbiome due to antibiotic therapy. Usage of antimicrobials disrupts the normal gut 
microbiota allowing for the colonization of C. difficile, resulting in fever, severe diarrhea and 
colitis [117]. Research has begun linking the alteration of the microbiome to obesity. Ley et al. 
noted significant changes in the dominant gastrointestinal microbial species in obese mice 
compared to lean mice [118]. Correspondingly, mice given the fecal extract from an obese twin 
subsequently led to weight gain, while the extract from the leaner twin did not [119]. Infants 
treated with ampicillin/gentamicin soon after birth showed a decrease in beneficial gut species 
that did not recover within 8 weeks post treatment and increased the incidence of weight gain 
[120, 121].  
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 This brings in to play the rationale for alternative strategies such as narrow-spectrum or 
pathogenic-specific antimicrobials. Improvements in diagnostics have decreased the time it takes 
to identify the etiological agent and narrow-spectrum treatment can be more cost effective long-
term. Antibiotics drug design against a limited population may also lead to faster discovery rates 
as targets will not need to be conserved or effective across a range of disparate species. With 
rising resistance, the necessity of maintaining the healthy microbial population and progress in 
general antimicrobial development of novel approaches are imperative.  
Strategies in antimicrobial drug discovery.  Drug discovery is a multi-step process spanning 
from target selection to drug optimization and clinical trials [122]. Historically, there have been 
two main approaches to antimicrobial drug discovery: empirical screening and target-based 
discovery (Fig 1). The empirical approach involved whole-cell based, trial and error screening of 
naturally occurring compounds or their synthetic derivatives. Compounds displaying growth 
inhibition against the desired spectrum of bacteria would be screened for eukaryotic cytotoxicity, 
followed by secondary screening to identify the mode of action. Biological assays would be used 
to verify the activity of the compound, ending with optimization and development for clinical 
trials [97]. By the early 1990s it was clear, even though successful in the past, this could no 
longer provide the results needed. The decreasing success of this process was due to the fact it 
was: (1) expensive and time consuming, while yielding a poor return for the effort [94, 123]; (2) 
had been depleted of easily obtainable products isolated from organisms culturable at the time 
[97]; and (3) changes in regulatory policies made it increasingly difficult to obtain clinical 
approval [124].  
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Figure 1. Workflow for two methods of antimicrobial drug discovery. 
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In 1995, the DNA sequence for the genome of Haemophilus influenza was completed 
[125], promising new approaches for the challenges in drug discovery and renewed excitement 
by various pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, Pfizer, and 
Wyeth [126]. Before then, few genome maps were publicly available, leaving researchers with 
the ability to only examine small areas of a specific sequence. With increased computational 
power and the availability of whole genomes, bioinformatics analysis allowed for the 
examination of new gene targets from various species [127]. Screening strategies then shifted to 
target-based drug design. The initial strategy was to focus on identifying as many potential 
targets available within a genome and one could then work to inhibit the targets by a high-
throughput screening (HTS) of drug-like compounds instead of blindly searching for compounds 
with antibacterial activity [97]. One prime example of the boom in research during the genomic 
age was that of GlaxoSmithKline (GSK). From 1995-2002, GSK attempted to identify a 
compound with Gram-positive or broad-spectrum antimicrobial activity. Using Streptococcus 
pneumoniae as the primary comparison genome, GSK analyzed genes across five pathogens for 
highly-conserved sequences resulting in more than 350 S. pneumoniae, S. aureus, and H. 
influenzae candidate target genes. From the 350 potential genes, 127 were classified as essential 
in vitro in at least one of the three organisms and 64 targets displayed attenuated growth in vivo. 
The company screened targets against more than 250,000 compounds from their library [126]. 
The screening led to 16 positive ‘hits’, five which went on to ‘lead’ compounds. Of the five 
targets (FabH, FabI, peptide deformylase, methionine tRNA synthetase, and phenylalanine tRNA 
synthetase) only one, peptide deformylase, led to an optimized lead molecule (GSK 1322322) 
that successfully went on to Phase II clinical trials [124, 126, 128]. The disappointing results 
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produced during these large screens were partially due to the newness of the era, the lack of 
knowledge of suitable targets and the feasibility of the HTS [97, 126].  
 Current strategies shifted towards a rational structure-based approach due to technological 
advances in genomic sequencing, high resolution protein structures and computational modeling. 
This led to a better understanding of the bacteria and target proteins [97, 129-131]. The basic 
concept is that the structural properties of a specific target relates to its biological activity and 
modification of the target will have therapeutic effects. Computer-aided molecular modeling of 
protein structures allows for virtual HTS screening of compounds rationally determined to interact 
with the target [131]. As a result, the initial trial-and-error of drug discovery is reduced as inhibitors 
are selected based on structural properties and there are increases in the screening efficiency since 
compounds have a higher chance of binding [129]. This approach was successful in the relatively 
rapid design of Iclaprim, a structural derivative of trimethoprim. Trimethoprim resistance in S. 
aureus is a result of a single amino acid substitution of the target dihydrofolate reductase (DHFR), 
resulting in a 20-fold decrease in affinity due to the loss of a hydrogen bond. Through molecular 
modeling of the mutated DHFR, Iclaprim was designed with a trimethochromene side chain in 
place of the original trimethophenyl resulting in a 20-fold increase in binding affinity, maintaining 
potency [97, 132].  
  
IV. Summary  
 
Currently, supplemental therapy for destructive periodontal disease can include the application of 
broad-spectrum antibiotics [133-135]. However, we now know that this is not ideal as it can alter 
the essential microbiome and runs the risk of promoting antibiotic resistance. While the oral 
cavity is a complex poly-microbial environment, it is evident that the interaction of specific 
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species disrupts the oral homeostasis, triggering the onset of periodontal disease. The hypothesis 
of P. gingivalis being a key player in the initiation of periodontitis suggests the potential for 
novel narrow-spectrum therapeutics. By targeting the key pathogens, it may be possible to treat 
periodontitis while allowing for the recolonization of the beneficial, healthy flora. In this study, 
we present a unique approach to predict essential gene targets selective for the periodontal 
pathogen within the oral environment. We then utilize a rational-based approach to identify 
small-molecule inhibitors for the potential development of antimicrobial agents against P. 
gingivalis and periodontal disease. We believe by using P. gingivalis and periodontal disease as a 
model we can begin to develop an approach for pathogen-specific antimicrobial drug discovery.  
 
V. Outline 
Following the general introduction and summary, the main goals of this dissertation are divided 
into three chapters. Background, methodologies, results and discussion relating to the specific 
aim are reported for each chapter.  
Chapter One focuses on the development and verification of the framework for a novel essential 
gene prediction model. The benefit of the model is displayed through the quick and accurate 
selection of a potential species-selective drug target in the Gram-negative periodontal pathogen, 
P. gingivalis. 
Chapter Two continues the evaluation of the potential drug target identified in Chapter One. 
The application of a CBDD method is used to identify new target specific inhibitors. 
Chapter Three details the biochemical screening from the compounds identified in Chapter 
Two.  A target-based and whole-cell based approach is used to assess in vitro activity. 
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This is concluded with an overall summary and conclusion. 
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Chapter One 
Applying a Novel Framework for the Prediction of Essential Genes as 
Antimicrobial Targets 
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Background 
With the onset of the genomics era came the availability of completed genome sequences and put 
new focus on the study of essential genes that held the promise of a wealth of biological and 
genomic data. Identification of these genes enhances our knowledge of gene regulatory networks 
[136] and aids in our understanding of cellular functions [137]. They can provide clues to the 
origins of life through the examination of the minimal genome [138] and evolutionary 
divergence [136, 137, 139]. Additionally, the understanding of the minimal number of genes 
required to sustain life supports research for the developing field of synthetic biology [138, 140]. 
Essential genes, by definition, are critical for the growth and/or survival of an organism. 
Antimicrobials target key metabolic and cellular functions, making essential genes attractive 
targets for drug discovery. Hu et al. was able to successfully identify drug targets for the fungus 
Aspergillus fumigatus from in vivo mouse model essential gene studies [141]. This has become 
more important with increasing rates of antibiotic resistance. Furthermore, the discovery of 
genome-wide essential gene data can present previously unexplored therapeutic targets [99, 142]. 
To date, a variety of approaches have been utilized to identify essential genes in a number 
of organisms. Large-scale experimental approaches such as systematic single gene deletions 
[139, 143-147], random transposon mutagenesis [148-151] and RNA interference [152, 153] 
utilize gene disruptions to evaluate the viability of the organism. However, these approaches can 
be extremely time-consuming, expensive and technically difficult with certain microbial systems. 
Due to the large investment, comprehensive experimental essential gene data is not readily 
available for the majority of sequenced genomes [154]. Currently only 31 species have genome-
wide experimental data that has been deposited into the Database of Essential Genes (DEG) 
[155]. Computational assessment of bacterial systems offer alternatives to experimental 
25 
 
procedures. In silico methods rely on information garnered from experimentally identified 
essential genes to predict essentiality based on orthologous genes, protein expression, 
phylogenetic conservation, similar GC content and codon usage [136]. These bioinformatics 
approaches have recently become standard for the prediction of essential genes. Unfortunately, 
orthologous genes account for only a fraction of the total genome and as genetic diversity 
increases in phylogenetically unrelated organisms, prediction accuracy decreases due to variation 
in gene sequences, alternate cellular pathways and genetic redundancy [136, 156]. In addition, 
experimental essential gene data, which in silico approaches are based on, is only available in a 
fraction of species and differences in experimental parameters (bacteria grown in rich versus 
minimal medium), mutagenesis techniques (site-directed versus random transposon insertion) or 
simply the definition of essential has led to a lack of consensus, making predictions difficult 
[140, 142]. 
Previously, we conducted a genome-wide essential gene identification study in the Gram-
positive, early oral colonizer Streptococcus sanguinis using systematic single and double gene 
deletions [139]. These essential genes were grouped by specific categories based on their KEGG 
functional annotation. Once linked together, we were able to create a model of essential 
pathways and determined that essential genes were conserved within three major categories of 
biological function: maintenance of the cell envelope, energy production and processing of 
genetic information. These three features also follow the ideal for what is considered the core of 
the hypothetical minimal genome encompassing the basic components necessary for cell survival 
[138, 140, 157]. Studies show that although essential genes themselves may diverge or change, 
the essential function remains relatively unaltered [140]. From these observations we established 
a framework to predict essential genes based on genome annotation and function. Our prediction 
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does not rely on sequence features among different species, but a gene’s contribution to an 
essential end product or the overall essential function that it plays. We believe that the reliance 
on genomic function instead of sequence addresses inconsistencies of essential gene data among 
different bacterial species as a result of genetic diversity while still allowing for an accurate 
prediction [140]. Furthermore, as a predictive method our approach simply requires a sequenced 
and annotated genome, bypassing the need for previous experimental data from closely related 
species. When lacking comprehensive essential gene datasets, we believe our approach provides 
a quick and accurate prediction of essential genes within the genome of different organisms. This 
could be extremely beneficial, especially when concerning drug target identification of emerging 
pathogens or difficult to culture organisms. Knowledge based on metabolic or gene functional 
networks have increasingly become an invaluable tool [158]. This was evident when a previous 
genome-scale study with metabolic networks, similarly based on genome information, showed 
high accuracy in the prediction of amino acid preference and by-product secretion rates [159].  
In this study, we demonstrate the framework for our essential gene predictive model is 
both accurate and useful for the identification of antimicrobial targets. First, using KEGG 
pathways and genome annotation, we identify relevant pathways and predict essential genes for 
the periodontal pathogen Porphyromonas gingivalis. The selection of P. gingivalis to evaluate 
our accuracy was valuable as it is phylogenetically distinct from S. sanguinis, from which the 
prediction model was derived. Second, we cross-validate our prediction with experimental data. 
During our study, P. gingivalis lacked a large-scale essential gene study. However, a genome-
wide Mariner-based transposon mutagenesis study was recently carried out [Klein BA, 
unpublished], allowing us to verify the accuracy of our prediction. Third, we identify P. 
gingivalis-selective essential gene targets, through the comparison of essential gene data sets 
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between the primary, non-pathogenic colonizer, S. sanguinis [139] and P. gingivalis. Last, based 
on “druggable” target criteria, we select a promising candidate target to experimentally 
characterize for future drug development studies.  
 
Materials and Methods 
Bacterial Strains, plasmids and growth conditions. Porphyromonas gingivalis W83 strain was 
cultured anaerobically (10% CO2, 10% H2, and 80% N2) at 37 °C in tryptic soy broth (TSB) 
(Becton Dickinson, Franklin Lakes, NJ) supplemented with 1 µg/ml menadione and 5 µg/ml 
hemin. When appropriate, erythromycin (Fisher Scientific, Fair Lawn, NJ) was used at a 
concentration of 5 µg/ml. Plasmid pVA2198 (Richmond, VA) [160] was used to isolate the 
erythromycin resistance cassette.  
Prediction of P. gingivalis essential genes. The prediction of essential genes was based on data 
derived from Xu et al. [139]. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database [161] for the genome-wide analysis of P. gingivalis strain W83, pathways such as 
glycolysis and fatty acid biosynthesis that were related to the three broader categories previously 
described (maintenance of the cell envelope, energy production and processing of genetic 
information) were manually examined and a network of predicted essential pathways was 
determined. We identified genes whose function singularly contributed to the formation of an 
essential end product for each of the pathways within our described network. Alternative 
pathways would be noted for any essential pathways within our network and paralogs/isozymes 
of predicted essential genes would be noted and listed as putatively essential. The assigned KO 
numbers and path numbers of genes predicted to be essential were listed and grouped by 
biological function. Multiple KO numbers or path numbers from KEGG were often assigned for 
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a single gene if it was involved in different pathways. Predicted essential gene functions wrongly 
annotated or missing annotation would be predicted by BLAST comparison of genes with similar 
gene functions from phylogenetically similar species.  
Gene functions assignment. To determine putative gene function, protein sequences were 
searched against annotated Porphyromonas gingivalis strain W83. The Cluster of Orthologous 
Groups (COG) annotation [162] was downloaded from the NCBI database and essential 
pathways were analyzed via the KEGG database [161]. Putative gene functions and COGs were 
recorded for predicted essential genes and the total number of genes in the genome. Ratios of the 
number of essential genes for each COG and the total number of genes belonging to a specific 
COG category were calculated. 
Comparison of Essential Gene Homologs. To identify essential genes conserved in P. 
gingivalis W83, a comparative genomics analysis was performed. Thirty-one other organisms 
with essential genes annotated in the DEG v10.0 [163] were obtained and protein sequence 
conservation was determined by BLASTP. Significant matches (E <1e-5) were analyzed to find 
homologs to P. gingivalis genes. Protein sequence conservation was calculated by percent amino 
acid identity. 
Multiple sequence alignment. For the prediction of the substrate binding site, the protein 
knowledge database, UniProtKB/Swiss-Prot (www.uniprot.org) [164], was referenced for 
organisms with completed enzymatic and functional data for m-Ddh. This included 
Corynebacterium glutamicum ATCC 27405, Lysinibacillus sphaericus, Bacteroides fragilis 
ATCC 25285, Clostridium thermocellum ATCC 13032 and Ureibacillus thermosphaericus 
(Uniprot ID: P04964, Q9KWR0, Q5L9Q6, A3DDX7, G1UII1). Complete protein sequences 
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were obtained from the National Center for Biotechnology Information (NCBI, 
www.ncbi.nlm.nih.gov/) database. Sequence alignment analyses were then performed using the 
ClustalW multiple alignment [165] via the BioEdit program v7.1.7. The alignment figure was 
generated in Espript 3.0 [166] for visualization.  
Primer design and recombinant PCR product construction. Primer design was based on the 
method of Xu et al. [139]. Two sets of primers, F1/F2 (5’- CTC CGA ATA GCA AAC ATC 
TAC TG -3’ and 5’- GAA AAA TTT CAT CCT TCG TAG TCG AGC AGC CAT GCG C -3’) 
and F3/R3 (5’- GGG CAA TTT CTT TTT TGT CAT TTG TCA AAT CTG GGG G -3’ and 5’- 
GAT AAT CAT GCT TCG GAG ATG -3’), were designed to amplify a 1.2kb sequence 
upstream and downstream, respectively, of the P. gingivalis target gene. A third primer set, 
F2/R2 (5’- GCG CAT GGC TGC TCG ACT ACG AAG GAT GAA ATT TTT C -3’ and 5’- 
CCC CCA GAT TTG ACA AAT GAC AAA AAA GAA ATT GCC C -3’) was designed to 
amplify the 800 bp erythromycin resistance cassette (ErmR) containing the ermF gene from 
plasmid pVA2198. To minimize polar effects from mutagenesis, primers were designed to 
include stop codons within frame and the antibiotic resistance cassette was designed to run in the 
same orientation as the target gene to ensure transcription. The three PCR fragments were 
created using F1/R1, F2/R2 and F3/R3. All PCR reactions were performed with an initial 
denature of 98 ˚C for 30 sec, 30 cycles of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 36 sec and 
a final extension of 72 ˚C for 7 min. The PCR products were purified using QIAquick PCR 
Purification Kit (Qiagen, Valencia, CA); the three fragments were then combined in equal 
amounts and amplified again using F1 and R3 primers to generate the final linear recombinant 
product. The PCR reaction was performed with an initial denature of 98 ˚C for 30 sec, 30 cycles 
of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 1 min 36 sec and a final extension of 72 ˚C for 7 
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min. Phusion High-Fidelity Taq DNA polymerase (New England Biolabs, Ipswich, MA) was 
used in all reactions. 
Transformation. The electroporation method was adapted from Fletcher et al. [167]. Briefly, 
0.2 ml of an actively growing culture of P. gingivalis was used to inoculate 2 ml of TSB 
supplemented with yeast extract, hemin and menadione, which was then incubated overnight at 
37 ˚C. Five ml of the same medium pre-warmed to 37 ˚C was then inoculated with 0.5 ml of the 
overnight culture and was incubated for an additional 4 h (OD600 ≈ 0.7). The cells were harvested 
by centrifugation at 6,000 × g for 15 min at 4 ˚C and washed twice in 10 ml of ice-cold 
electroporation buffer (10% glycerol, 1 mM MgCl2). The final cell pellet was re-suspended in 
0.5 ml of electroporation buffer. A 100 l sample of re-suspended cells and 5 µg of DNA were 
placed in a sterile electrode cuvette (0.2-cm gap). The cells were then pulsed with a Bio-Rad 
(Hercules, Calif.) gene pulser at 2,500 V for 9.5 ms and incubated on ice for 5 min. The cell 
suspension was then added to 0.6 ml of TSB broth supplemented with yeast extract, hemin and 
menadione and incubated for approximately 16 h. A 100 l sample was plated on 5% sheep 
blood agar medium containing erythromycin and incubated anaerobically at 37 ˚C for 5 to 10 
days. 
 
Results 
Defining our framework of essential gene prediction. The definition of gene essentiality can 
vary between researchers, by experimental parameters and/or growth conditions. Genes that are 
essential for growth in minimal medium or during in vivo conditions may not necessarily reflect 
what is essential for survival in ‘ideal’ laboratory conditions. Also, a deletion or mutation of a 
defined essential gene may not be lethal but may lead to decreased fitness [168]. These 
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discrepancies are clear in the model organism Escherichia coli. Studies performed by several 
laboratories, showed clear differences in their definition and number of experimentally identified 
essential genes. Gerdes et al. performed genome-wide transposon mutagenesis in 2003, where 
they identified 609 essential genes [169], the Keio collection is currently defined as 296 essential 
genes [143] and a metabolic study described 119 genes as being conditionally essential [170]. In 
this study we focused our prediction on genes we considered to be necessary for growth in rich 
media, implying that certain vitamins, amino acids and nucleotide precursors would be provided. 
These genes represent the ‘core’ of the cell’s biological and cellular functions and would be 
considered essential in typical experimental in vitro conditions [171]. Furthermore, as these core 
essential functions are crucial to bacterial fitness, they represent a set of genes less affected by 
evolutionary processes [172-174]. 
From experimental studies in S. sanguinis SK36 [139], we saw that, while essential genes 
were distributed in various pathways, they could be associated through key biochemical 
pathways or functions. Genes required for peptidoglycan biosynthesis, terpenoid backbone 
biosynthesis, glycerophospholipid metabolism and fatty acid biosynthesis all related to the 
maintenance of the cell envelope. The pentose phosphate pathway and glycolysis provided 
energy. Nucleotide biosynthesis, DNA replication, cell division proteins, and protein 
biosynthesis were associated with the processing of the cell’s genetic information. In order to 
predict essential genes, we identified essential metabolic pathways corresponding to the three 
core biological functions. The functional genome annotation was obtained from the KEGG 
database and assigned to genes within the pathways. Our approach defined essential as a gene 
whose functional role individually contributed to the formation of a crucial chemical compound. 
Therefore the single deletion or mutation of the gene would result in a non-viable cell.   
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Prediction of essential genes by gene annotation in P. gingivalis strain W83. To predict 
essential genes in P. gingivalis strain W83, we manually examined our essential biochemical 
pathway maps through the KEGG database, a workflow schematic is shown in Fig. 2. Annotated 
genes were viewed for each pathway and from 1909 protein coding genes, 212 were predicted to 
be essential (Fig. 3, for complete list, see Appendix, Supp. Table 1). During our prediction, we 
noted several instances of paralogs or potential isozymes (PG1852/PG0223, exonuclease, DNA 
polymerase III subunit epsilon; PG0121/PG1258, DNA binding protein HU; and 
PG1940/PG0933, elongation factor G). Many paralogous genes code for proteins that have 
redundant functions, which is why a majority of computational models predict them to be non-
essential. However, it has also been noted that paralogous genes can have distinct roles through 
functional divergence [175]. For example, N. meningitidis possess paralogous genes for 
glyceraldehyde-3P dehydrogenase (NMB2159 and NMB0207). However, only NMB2159 was 
determined to be essential, as NMB2159 is involved in glycolysis and NMB0207 is involved in 
gluconeogenesis [176]. As experimental data would be needed to determine if both or one gene 
was essential, we listed paralogs as potentially essential. Hypothetical proteins were left out of 
our analysis unless a conserved motif and putative function was noted in the KEGG database. 
One such example was PG2046, which was annotated as a hypothetical protein in the KEGG 
database. Based on our database searches the gene contained a conserved tRNA 
methyltransferase motif and had orthologous matches to other tRNA(Ile)-lysidine synthases. 
This indicated that the gene might have a putative essential function in tRNA processing. 
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Figure 2. Workflow schematic for the prediction model framework. 
(a) A strategy to predict essential genes. (b) Example of an essential pathway from S. sanguinis strain 
SK36. Circles represent key intermediates; green boxes represent essential genes; red boxes represent 
non-essential genes; white boxes represent genes not present within the genome of S. sanguinis. 
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Figure 3. Predicted essential genes and corresponding pathways for P. gingivalis strain W83.  
The three biological categories associated with essential genes, previously determined from experimental 
studies in S. sanguinis SK36, are indicated by color: dark blue, maintenance of cell envelope; grey, 
energy production; light green, processing of genetic information. Predicted essential gene numbers 
(PG#) are shown in red, predicted non-essential genes are shown in black. Solid arrows indicate 
enzymatic reaction, dashed arrows dashed arrow, multistep pathway; blue dashed arrow, products 
involved in cell wall and membrane formation; block arrow, product from one pathway serving as input 
to another pathway; oval with bold arrow, transporter; slash, separating paralogs. Ado, adenosine; Cyd, 
cytidine; DAG, 1,2-diacylglycerol; DHAP, dihydroxyacetone phosphate; DHF, dihydrofolate; L-G3P, sn-
glycerol 3-phosphate; Guo, guanosine; LPA, lysophosphatidic acid; LTA, lipoteichoic acid; PA, 
phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; PGP, 
phosphatidylglycerophosphate; PG, phosphatidylglycerol; PPP, pentose phosphate pathway; LPS, 
lipopolysaccharide; THF, tetrahydrofolate; Urd, uridine. Genes assumed to be essential based on 
prediction, but not annotated in the KEGG database, are represented by red letters (see Table 1). Predicted 
essential genes associated with ribosome and aminoacyl-tRNA biosynthesis are not indicated here. For 
the complete essential gene prediction see Appendix, Supp. Table 1. 
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From our assessment of the core essential pathways, we knew certain genes should be 
critical to the formation of certain compounds. However, during our analyses we saw that a small 
fraction of genes were missing annotations for certain essential functions in the KEGG database, 
noted in Fig. 3 as lowercase letters. For example, in the glycolysis pathway, the gene responsible 
for the conversion of pyruvate to acetyl-CoA is not noted. To identify these missing genes, we 
compared the genome of P. gingivalis against annotated genes in the NCBI database using a 
BLASTP analysis. Proteins with e-values of 1×10-8 or less were then prioritized and missing 
genes were identified by their potential function or motif (Table 1, Fig. 3).     
There is no direct correlation between the number of essential genes and the total number 
of genes in the genome as different experimental approaches or conditions may derive various 
outcomes. However, on average, essential genes account for around 10-20% of the genome. S. 
sanguinis SK36 with 2270 protein encoding genes has 218 essential genes or 9.6% of the 
genome [139], S. pneumoniae D39 with 2,046 ORFs has 244 essential genes or 11.9% [146, 147] 
the 4,291 protein encoding genes in E. coli MG1655, 620 were assessed to be essential or 14.4% 
[169]. B. subtilis 168 resulted in 271 essential genes from a total ORF of 4,099 genes, accounting 
for 6.8% of the genome [145] and P. aeruginosa contains 678 putatively essential genes from 
5,500 genes or approximately 12% [177]. Our prediction of 212 essential genes accounted for 
11% of the genome, fitting with the expected percentage of essential genes within a microbial 
genome. Nonetheless, this prediction may not be comprehensive. Some genes could have been 
overlooked due to a lack of biological data annotated in the KEGG database, for instance the 
lack of annotation for hypothetical genes.  
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Table 1. Non-annotated predicted essential genes in P. gingivalis strain W83. 
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Functional analysis and examination of predicted essential genes by biological categories. 
To ensure that our essential genes followed our model, we next examined them to determine if 
they were associated with the three major biological categories. The predicted essential genes in 
P. gingivalis were grouped into a pathway based on the KEGG pathway orthology (KO number) 
and the final end product. Of the 212 predicted genes, 46 genes fell into the maintenance of the 
cell envelope category. About 32% (7% of total predicted essential genes) of those genes were 
directly related to peptidoglycan biosynthesis while about 19% (4% of total) were related to fatty 
acid biosynthesis. Sixteen genes were involved in energy production with about 69% (5% of 
total) related to glycolysis. The majority of the predicted essential genes (148 genes) were 
grouped into the processing of genetic information category. About 9% (6% of total) were 
related to nucleotide biosynthesis including both and pyrimidine metabolism and 33% (24% of 
total) were related to ribosomal biosynthesis. Two genes were involved in the synthesis of 
cofactors: PG0957, a riboflavin biosynthesis protein involved in FMN/FAD biosynthesis, and 
PG1896, annotated as S-adenosylmethionine (SAM) synthetase. Both of these genes fit into a 
variety of metabolic roles, producing energy which feed into other pathways (Fig. 4a). 
 To further study the functional characteristics of our predicted essential gene list, Clusters 
of Orthologous Groups of proteins (COG) [162] classifications were examined. COGs are 
defined through protein sequence comparison of completed genomes and functional categories 
such as RNA processing and modification, cell motility and lipid metabolism are grouped. A 
high number of genes predicted to be essential, were involved in translation, ribosomal structure 
and biogenesis (group J; Fig 4b) following other essential gene and minimal genome studies 
[143, 157, 162]. These COG functions belong to the information storage and processing category 
which includes critical cellular functions that require multiple proteins such as 30S and 50S 
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ribosomal proteins, cell division proteins and translation factors. However, the larger total 
proportion of genes belonged to COG functional groups that are related to metabolism (group C, 
E, F, G, H, I and Q; Fig 4b). COG assignments are influenced by genome annotation. Our 
prediction was mostly lacking hypothetical proteins without a functional annotation; therefore, 
only eight genes did not have a clearly defined COG function and are classified by general 
function. This included GTP-binding proteins era, obgE, engB and engA, acyl carrier proteins 
involved in fatty acid biosynthesis fabG and fabK, an oxidoreductase involved in peptidoglycan 
biosynthesis, and the ribonuclease Z elaC. This COG distribution is consistent with genes 
necessary for in vitro growth under laboratory conditions. Alteration in the environmental 
conditions would lead to changes in genes required for survival. Studies show that cells grown 
under chemically defined minimal media or during in vivo conditions were not enriched for 
translation, ribosomal structure and biogenesis (group J), but for amino acid 
transport/metabolism (group E), nucleotide transport/metabolism (group F) and energy 
production/conversion (group C) [178]. This suggests there are different needs for different 
environmental conditions.  
Cross-validation of prediction with experimental validation of essential genes in P. 
gingivalis strain W83. To evaluate our model, we performed a comparison of the predicted 
essential with putative experimental essential gene data. A transposon mutant library was 
generated in P. gingivalis strain W83 using a pSAM_Bt-based Mariner mutagenesis vector as 
previously carried out in Klein et al. for the genome-wide mutagenesis of P. gingivalis strain 
ATCC 33277 [149]. Approximately 20,000 colonies were pooled following multiple separate 
transpositions. Strain W83 proved difficult to obtain transposon mutants, which may be a result  
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Figure 4. Pathway association and COG distribution for predicted essential genes in P. gingivalis 
strain W83. 
(a) Distribution of predicted essential genes divided by pathway and three conserved biological functions. 
(b) The number of predicted essential genes and the percent distribution for the total number of predicted 
essential genes were calculated for the individual COG function.  
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of known capsule and fimbriae structures, characteristic of this strain. A small degree of 
resistance to the selective antibiotic (Erm) was also observed, which may point to survival of a 
mutant clone being correlated with the expression level of the Erm cassette. Following Illumina 
sequencing of two technical replicates, it was determined that about 12,000 distinct insertion 
mutants were present in the strain W83-background mutant pool. Around 12,000 insertions is 5-
fold coverage of the genome, which is sub-optimal for characterization of gene essentiality. 
Based on the limited number of insertions relative to the 36,000 distinct insertions in the ATCC 
33277-background, we decided to focus on grouping genes as either containing zero insertions or 
greater than two insertions, corresponding to putatively essential and putatively non-essential 
respectively (Appendix, Supp. Fig. 1) With this grouping guideline, 759 putatively essential and 
680 putatively non-essential genes were noted. It is important to note that the guidelines for 
determining putatively essential and non-essential in strain W83 were not as stringent as those in 
the previous study for strain ATCC 33277 due to the different library complexities. 
  From 212 predicted essential genes, 173 matched the experimental data, giving us a 
prediction accuracy of 81.6% (Fig 5, Supp. Table 1). Of the predicted essential genes not 
experimentally validated, three of these genes (PG0223, DNA polymerase III subunit epsilon; 
PG0121, DNA binding protein HU; PG0933, elongation factor G) may have been essential if not 
for possible isozymes or paralogs to predicted essential genes that were validated (PG1852, 
PG1258, PG1940, respectively). A large subset was annotated as hypothetical and therefore 
could not be predicted by our model without an assigned cellular function. A majority of these 
genes coded for functions that play multiple, non-specific roles. For example, there were several 
ABC transporters, ATP-binding proteins, glycoslytransferase and putative transcriptional 
regulators. In addition, many of these genes were not linked or associated with biochemical 
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pathways in KEGG. Lacking this information made it difficult to assess the essential role the 
gene would play to the overall cell survival. KEGG annotations are not necessarily the most up-
to-date.  
Although we were interested in the prediction of essential genes, to further validate the 
accuracy of our model, we compared the predicted essential genes to the experimentally 
determined non-essential genes to see if there was any overlap between the two data sets. From 
680 observed non-essential genes in strain W83 (Appendix, Supp. Table 1), only 7 genes (or 3% 
total) were predicted to be essential by our model (Fig. 5). These few false positives were again 
due to the presence of potential isozymes, paralogs or alternative pathways. PG0223 and 
PG1852, for example, both encode exonuclease DNA polymerase III subunit epsilon involved in 
DNA replication. While PG1852 is putatively essential, PG0223 is not. Mis-predictions may also 
come from lack of, or incorrect, annotation. In glycolysis, the conversion of PEP to pyruvate by 
the irreversible enzyme pyruvate kinase should be essential for energy production by the cell. 
However, the annotation for pyruvate kinase was missing in KEGG for P. gingivalis. A 
reversible enzyme with a similar function, pyruvate phosphate kinase, is found in some bacteria 
for the conversion of pyruvate to PEP and this enzyme was present and annotated as PG1017. 
Due to the lack of annotation for pyruvate kinase, we predicted pyruvate phosphate kinase to 
play that essential function. As PG1017 was experimentally shown to be non-essential, it is 
likely pyruvate kinase has not been noted within the database or another enzyme must be present. 
A small number of genes (32 out of 212) were unaccounted for in both the non-essential and 
essential experimental data. As mentioned earlier, due to complexities in the experimental 
conditions, some genes could not be accurately assigned to a category and therefore left out of 
the analysis.  
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Figure 5. Cross-validation of prediction to experimental essential gene data. 
(a) The number of essential genes shared between those predicted and the experimentally identified 
essential and non-essential gene data. (b) The comparison of the number of essential genes between the 
predicted essential genes, experimentally identified essential genes and experimentally determined non-
essential genes for strain W83 is shown. The blue circle represents the number of predicted genes 
correlated with experimental data, orange the number of predicted essential genes correlated with non-
essential from experimental data and gray the number of predicted essential genes not accounted for in 
experimental data. Approximately 81% of genes predicted to be essential (173 of 212) matched the 
experimental essential data set, and only a small fraction (7 of 212) of genes predicted to be essential 
were shown to be non-essential. 
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Comparison of P. gingivalis and S. sanguinis essential genes. We next compared the essential 
gene data predicted for P. gingivalis strain W83 to the experimental data of S. sanguinis strain 
SK36. As the healthy oral cavity is composed of roughly 80% streptococcus species [179], we 
theorized that selecting orthologous essential genes in P. gingivalis that were absent or not 
essential within S. sanguinis would present us with potential antimicrobial targets selective 
within the oral cavity for periodontal pathogens. We identified 68 essential genes that were 
selective for P. gingivalis (Table 2). It was clear during our analysis that differences were mostly 
a result of alternative pathways or genes apart of complexes that we predicted to be essential to 
the overall function. A clear example is in regards to cell wall composition. Gram-negative 
bacteria possess an outer membrane composed of lipoposaccharide and lipoproteins with a high 
lipid content. Gram-positive bacteria express lipoteichoic acid on the cell membrane and is 
composed of a high peptidoglycan content. This gave us a different set of essential genes for cell 
envelope maintenance. Another key difference lay in terpenoid biosynthesis. S. sanguinis uses 
the mevalonic acid pathway, producing terpenoids via the HMG-CoA reductase pathway. 
However, P. gingivalis uses the alternate MEP/DOXP or non-mevalonate pathway.  
Identification and assessment of meso-diaminopimelate as a target. To assess the value of 
our model in drug discovery, we wanted to examine the list of P. gingivalis-selective essential 
genes for future therapeutic targets. Sequences for each gene was first searched against the 
human genome to eliminate genes with significant human homology. No genes within our list 
had a homologous sequence compared to the human genome. Based on what we know of 
bacterial metabolism, the lysine biosynthesis pathway presented an attractive option for 
pathogen-selective targeting. Lysine is a required amino acid for bacteria and especially  
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Table 2. Predicted P. gingivalis-selective essential genes. 
Functional 
category 
KEGG Pathway 
KEGG 
KO# 
GeneID Name Protein ID 
Cell envelope 
Peptidoglycan 
biosynthesis 
K03340 PG0806 - 
Gfo/Idh/MocA family 
oxidoreductase 
K01921 PG0729 Ddl 
D-alanyl-alanine 
synthetase A 
K01929 PG1106 murF 
D-Ala-D-Ala adding 
enzyme 
K01000 PG0577 mraY 
phospho-N-
acetylmuramoyl-
pentapeptide-transferase 
K02563 PG0580 murG 
N-acetylglucosaminyl 
transferase 
K05366 PG0794 pbp1a 
penicillin-binding 
protein 1A 
K03587 PG0575 - 
penicillin-binding 
protein 2 
K00215 PG2002 dapB 
dihydrodipicolinate 
reductase 
K00928 PG2189 lysC aspartate kinase 
K00133 PG0571 asd 
aspartate-semialdehyde 
dehydrogenase 
K01714 PG2052 dapA 
dihydrodipicolinate 
synthase 
Terpenoid backbone 
biosynthesis 
(MEP/DOXP pathway) 
K01662 PG2217 dxs 
1-deoxy-D-xylulose-5-
phosphate synthase 
K00099 PG1364 dxr 
1-deoxy-D-xylulose 5-
phosphate 
reductoisomerase 
K00991 PG1434 ispD 
2-C-methyl-D-erythritol 
4-phosphate 
cytidylyltransferase 
K00919 PG0935 ispE 
4-diphosphocytidyl-2-C-
methyl-D-erythritol 
kinase 
K01770 PG0028 ispF 
2-C-methyl-D-erythritol 
2,4-cyclodiphosphate 
synthase 
K03526 PG0952 ispG 
4-hydroxy-3-methylbut-
2-en-1-yl diphosphate 
synthase 
K03527 PG0604 ispH 
4-hydroxy-3-methylbut-
2-enyl diphosphate 
reductase 
Terpenoid backbone 
biosynthesis 
K00806 PG0190 uppS 
undecaprenyl 
pyrophosphate 
synthetase 
Polysaccharide 
transporter 
- PG0117 - 
polysaccharide transport 
protein 
Lipopolysaccharide 
biosynthesis 
K00677 PG0070 lpxA 
UDP-N-
acetylglucosamine 
acyltransferase 
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K02372 PG0071 lpxC 
bifunctional UDP-3-O-
[3-hydroxymyristoyl] N-
acetylglucosamine 
deacetylase/(3R)-
hydroxymyristoyl-ACP 
dehydratase 
K02536 PG0072 lpxD 
UDP-3-O-[3-
hydroxymyristoyl] 
glucosamine N-
acyltransferase 
K00912 PG0638 lpxK 
tetraacyldisaccharide 4'-
kinase 
K02527 PG1565 - 
3-deoxy-D-manno-
octulosonic-acid 
transferase 
K02517 PG2222 - acyltransferase 
Glycerophospholipid 
metabolism/glycerolipi
d metabolism 
K00057 PG1369 gpsA 
glycerol-3-phosphate 
dehydrogenase 
K00980 PG2068 tagD 
glycerol-3-phosphate 
cytidylyltransferase 
Energy 
production 
Glycolysis / 
Gluconeogenesis 
K01835 PG2010 pgm phophomannomutase 
K04041 PG0793 fbp 
fructose-1,6-
bisphosphatase 
K15634 PG1513 - 
phosphoribosyltransferas
e/phosphoglycerate 
mutase 
K01006 PG1017 ppdk 
pyruvate phosphate 
dikinase 
K01610 PG1676 pckA 
phosphoenolpyruvate 
carboxykinase 
Pentose phosphate 
pathway 
K01619 PG1996 deoC 
deoxyribose-phosphate 
aldolase 
Nicotinate and 
nicotinamide 
metabolism 
K00763 PG0057 pncB 
nicotinate 
phosphoribosyltransferas
e 
K01950 PG0531 nadE NAD synthetase 
Genetic 
information 
processing 
Pyrimidine metabolism 
K00384 PG1134 trxB thioredoxin reductase 
K00945 PG0603 cmk cytidylate kinase 
Purine 
metabolism/Pyrimidine 
metabolism 
K00525 PG1129 nrd ribonucleotide reductase 
Folate biosynthesis K01633 PG2091 folB 
dihydroneopterin 
aldolase 
DNA replication 
(DNA polymerase III) 
K02342 PG1852 - 
exonuclease (DNA 
polymerase III subunit 
epsilon) 
K02342 PG0223 - 
exonuclease (DNA 
polymerase III subunit 
epsilon) 
Ribosome K02919 PG1915 rpmJ 
50S ribosomal protein 
L36 
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K02916 PG0990 rpmI 
50S ribosomal protein 
L35 
K02895 PG1927 rplX 
50S ribosomal protein 
L24 
K02897 PG0167 rplY 
50S ribosomal protein 
L25 
K02876 PG1919 rplO 
50S ribosomal protein 
L15 
K02907 PG1920 rpmD 
50S ribosomal protein 
L30 
K02888 PG0314 rplU 
50S ribosomal protein 
L21 
K02904 PG1930 rpmC 
50S ribosomal protein 
L29 
K02952 PG1914 rpsM 
30S ribosomal protein 
S13 
K02956 PG1758 rpsO 
30S ribosomal protein 
S15 
K02996 PG0376 rpsI 
30S ribosomal protein 
S9 
Aminoacyl-tRNA 
biosynthesis (tRNA 
synthetase) 
K01886 PG1951 glnS 
glutaminyl-tRNA 
synthetase 
K01893 PG1121 asnC 
asparaginyl-tRNA 
synthetase 
K01876 PG0153 aspS 
aspartyl-tRNA 
synthetase 
(tRNA processing) 
K04075 PG2046 - 
hypothetical protein: 
tRNA(Ile)-lysidine 
synthase 
K00566 PG0268 mnmA 
tRNA-specific 2-
thiouridylase MnmA 
Translation factors 
(Elongation factors) 
K02519 PG0255 infB 
translation initiation 
factor IF-2 
Protein export K12257 PG1762 secDF 
bifunctional preprotein 
translocase subunit 
SecD/SecF 
Chaperones and 
folding catalysts 
(Protein folding) 
K00970 PG0801 - poly (A) polymerase 
GTP-binding proteins K03595 PG2142 era GTP-binding protein Era 
Chromosome 
partitioning proteins 
(cell division) 
K03590 PG0583 ftsA 
cell division protein 
FtsA 
K03798 PG0047 ftsH 
cell division protein 
FtsH 
K03589 PG0582 ftsQ 
cell division protein 
FtsQ 
K03569 PG1396 mreB 
rod shape determining 
protein MreB 
K03570 PG1395 mreC 
rod shape determining 
protein MreC 
Cofactors Riboflavin metabolism K11753 PG0957 ribF 
riboflavin biosynthesis 
protein RibF 
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interesting is the dual role the pathway plays in lysine and peptidoglycan biosynthesis, making 
evident its potential for antimicrobial therapy. However, what makes lysine biosynthesis suitable 
for species-selective targeting is the presence of pathway variants (Fig. 6). The pathway is 
composed of four different branches, differing by the substrate intermediates at the branch point 
of L-2, 3, 4, 5-tetrahydrodipicolinate’s (THDP) conversion to meso-diaminopimelate (m-DAP). 
The succinylase branch utilizes succinyl-CoA to generate succinylated intermediates; similarly, 
the acetylase branch utilizes acetyl-CoA to produce acetylated intermediates. These two variants 
are used by the majority of Gram-negative and Gram-positive bacteria. The aminotransferase 
branch, used by plants and methanococci, involves a single step amine transfer to produce the 
precursor of m-DAP, LL-DAP [180]. However, for P. gingivalis, m-DAP [181-185] is directly 
produced by meso-diaminopimelate dehydrogenase (m-Ddh; PG0806; GenBank ID: 
AAQ65966.1) in a single step [181-185]. This led us to focus on m-Ddh as a potential target to 
pursue. To further narrow selectivity, microbes from the Human Oral Microbiome Database 
(HOMD) with an annotated m-Ddh were collected and aligned against m-Ddh in P. gingivalis. 
Out of 315 sequenced genomes, 69 contained an ortholog to m-Ddh. Interestingly, these 69 
species mostly included known pathogens such as Prevotella sp., Tannerella sp. and Veillonella 
species. This indicated the target could be useful across multiple pathogens contributing to 
periodontal diseases. 
An important component in antimicrobial therapy is the ability to target critical biological 
processes required for bacterial cell survival. Historically, these targets have focused on key 
biological functions such as DNA replication, protein translation and cell wall biosynthesis 
[186]. While m-Ddh is involved in protein and cell wall biosynthesis and we predicted the gene 
to be essential, prior to the beginning of our study we did not know whether this was  
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Figure 6. Variant pathways of lysine and meso-diaminopimelate biosynthesis. 
Genes involved in the enzymatic reactions are omitted for general overview with the exception of the 
dehydrogenase pathway. Figure adapted from Born et. al. 
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experimentally true. To verify m-Ddh was essential in P. gingivalis strain W83, we knocked out 
the gene by transforming cells with a recombinant PCR product carrying an erythromycin 
resistance cassette (ErmR) allowing for allelic replacement mutagenesis within the genome. 
Through this method, the antibiotic resistance cassette replaces the target gene and, if essential, 
results in non-viable cells following transformation. The disruption of the PG0806 gene with the 
ErmR cassette resulted in no colony formation following electroporation and recovery in 
selective media (Fig. 7a). This result was repeated independently; suggesting that deletion of 
PG0806 is lethal to P. gingivalis and therefore essential. To show that the lack of colony 
formation was in response to the essentiality of the gene and not problems with the 
transformation, we simultaneously carried out allelic replacement mutagenesis for a non-
essential hypothetical membrane protein (GenBank ID: AAQ65282.1). For this control we were 
able to obtain substantial colony formation (Fig. 7b). 
Another component for a potential target is “druggability” or the chance a small-molecule 
will bind and have a significant effect on the protein’s activity [187]. Druggability can be 
assessed in several methods, e.g., proof-of-concept in similar proteins, conserved or targetable 
sequence motifs and structural analysis [188]. m-Ddh enzymes from several organisms 
referenced in UniprotKB/Swiss-Prot with known or binding sites predicted by similarity were 
aligned (Fig. 8). P. gingivalis has approximately 30% sequence identity to C. glutamicum, L. 
sphaericus, C. thermocellum and U. thermosphaericus and 70% sequence identity to B. fragilis. 
When analyzing the sequences of m-Ddh we found that the binding pocket for m-DAP was 
highly conserved. Druggable proteins have been shown to consist of a higher ratio of non-polar 
to polar amino acid residues (m-Ddh; 59.1% vs 40.9%) and a lower isoelectric point 
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Figure 7. Allelic replacement mutagenesis for predicted essential gene target, m-Ddh. 
(a) Predicted essential gene PG0806 was transformed and plated on selective media resulting in no colony 
formation compared to (b) a non-essential gene control, validating the prediction that m-Ddh was 
essential.  
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(m-Ddh: 5.39 vs 7.44 in non-targets). Analysis showed that m-Ddh contains an oxidoreductase 
domain, a favored targeted enzyme class [189] and which has been previously determine with 
high confidence to be “druggable” by the Druggable Cavity Directory. Structural analysis by 
SYBYL revealed a solvent inaccessible binding cavity with residues corresponding to the m-
DAP sequence alignment and the conserved motifs (Fig. 9). This binding cavity consists of a 
relatively deep and hydrophobic region which should consist of hydrophobic amino acid residues 
such as methionine, tryptophan and phenylalanine (Fig. 9). In addition, m-Ddh from C. 
glutamicum has been co-crystallized in a complex with the endogenous substrate [190]. 
Therefore, m-Ddh structure appears to be “druggable”, making it a suitable target for drug 
discovery.   
 
Discussion 
We aimed to present a quick and efficient manner to identify putative essential genes in bacterial 
species lacking genome-wide experimental data. This would be of great benefit, especially 
during drug discovery for emerging and re-emerging pathogens. Essential genes present novel 
targets for overcoming antibiotic resistance and developing new antimicrobial drug therapies. 
Genome-wide experimental efforts can be expensive and time-consuming, which has resulted in 
an increase in predictive methodologies. We established a framework for a novel approach 
derived from previous studies in a Gram-positive bacterium S. sanguinis [139]. We showed that 
essential genes can be linked to pathways related to three basic biological categories allowing for 
the prediction of essential genes based on gene function and annotation, subverting the need for 
orthologous genes comparison.  
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Figure 8. Sequence analysis of m-Ddh. 
(a) Sequence alignment of m-Ddh from other bacterial organisms. The multiple sequence alignment 
analyses were performed using the T-Coffee multiple alignment. Alignment figure was generated in 
ESpript 3.0 The putative binding sites of Corynebacterium glutamicum (Cg), Lysinibacillus sphaericus 
(Ls), Bacteroides fragilis (Bf), Clostridium thermocellum (Ct) and Ureibacillus thermosphaericus (Ut) 
cited in the sequence annotations in UniProtKB/Swiss-Prot and P. gingivalis (Pg) predicted based on 
homology are indicated by astericks. The oxidoreductase domain for P. gingivalis is indicated by arrows 
below sequence. Secondary structure for P. gingivalis is annotated above the sequence. Relative 
percentage of characterized amino acid residues are shown below. (b) Secondary structure alignment of 
m-Ddh’s putative binding site from P. gingivalis (green), C. glutamicum (cyan) and U. thermosphaericus 
(purple). Key residues are labeled, side chains are displayed as sticks and colored corresponding to atom 
type. Hydrogens were omitted for clarity. 
 
60 
 
 
  
61 
 
 
  
Figure 9. 3D structural analysis of m-Ddh from P. gingivalis. 
Ribbon based structure of m-Ddh with the m-DAP binding domain. m-DAP binding cavity is displayed by 
wireframe surface and zoomed in view of cavity with corresponding a.a. residues labeled. Cavity colored 
by hydrophobicity (red = hydrophobic) is shown below.  
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In this study, we assessed the efficacy of our novel approach. By applying our gene 
annotation prediction model to the Gram-negative periodontal pathogen, P. gingivalis, and 
utilizing experimental data from a genome-wide transposon mutagenesis study performed in 
strain W83 of P. gingivalis, we showed that: 1) our assessment of essential pathways and 
knowledge of key genes within those pathways is accurate; 2) our model can easily be applied to 
a variety of bacterial species; 3) our prediction model may identify a core set of essential genes 
and provide important genomic data to refine our prediction model through the comparison of 
experimental data; 4) the benefit of having a bioinformatics/predictive approach together with an 
experimental approach; and 5) by applying our prediction model, we can accurately select a 
potential antimicrobial drug target.    
From 1909 protein encoding genes annotated in KEGG, we predicted 212 essential genes. 
These genes fit within the three assigned biological categories (maintenance of the cell envelope, 
energy production and processing of genetic information) reaffirming the backbone of our model 
of essential genes. Having the advantage of recent experimental data by Klein et al., we 
compared the two studies. The initial mutagenesis study was done in strain ATCC 33277 where 
463 essential genes were identified. However, a new transposon mutagenesis study was carried 
out in strain W83 for the direct comparison of essential genes. In this experimental study, 759 
putative essential genes were identified and a comparison resulted in roughly an 81% match to 
our model. It is important to note that the experimental data for strain W83 was not as 
comprehensive as the study from strain ATCC 33277, which is why not all the genes within the 
genome are accounted for. We also focused on what was determined to be putatively non-
essential, to determine if we had false-positive predictions. From the study, 680 genes were 
determined to be non-essential. Our model was also accurate in not predicting non-essential 
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genes as essential. Only 7 genes were predicted from our model, but the majority (3 out of 5) had 
isozymes or paralogs that were determined to be essential.  
Several limitations of our essential gene prediction model should be noted. First, our 
model does not identify hypothetical proteins as essential. Although hypothetical proteins may 
present a subset of undiscovered gene targets, it is unlikely that all of these genes would encode 
functions essential to the cell. During our experimental screen of S. sanguinis, out of 218 
essential genes, only three were annotated as hypothetical. We also found that three of the 
hypothetical proteins shown to be essential during the transposon mutagenesis should not be 
expressed under the experimental conditions [191]. Genes not expressed may lead to false 
positives in transposon or allelic replacement mutagenesis studies. Second, genes whose 
functions are incorrectly annotated or incomplete will decrease the accuracy of our prediction. 
This would lead to genes falsely predicted to be essential or missed during our analysis 
completely. Organisms whose genome annotation is incomplete would also result in missed 
prediction during our analysis. For example, the KEGG genome annotation of P. gingivalis W83 
is missing key enzymes in glycolysis for the conversion of PEP to pyruvate and pyruvate to 
acetyl-CoA. Another issue would be isozymes and/or paralogs. As our model is essentially 
predicting single gene knockouts, it would be difficult to determine whether one or both genes 
would be essential without experimental screening. Essential genes are predicted based on their 
biological function in regards to essential pathways. Ubiquitous genes or genes whose function is 
not linked to a specific pathway may be difficult to predict or may be missed. This is especially 
true for genes involved in genetic information processing. Many of these genes are involved in a 
variety of processes not defined to a specific biological functions. Lastly, genes can rarely be 
classified as absolutely essential or non-essential as the definition greatly depends on the 
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specified set of conditions [192]. Gene inactivation may result in a slow growth phenotype or a 
cell with decreased fitness that will die over time. For instance, deletion of the pyrophosphatase 
ppa gene in E.coli is viable for several hours until cellular pyrophosphates become too high, 
stopping cell growth [193]. Our model also assumed P. gingivalis cells were grown during in 
vitro conditions with rich media. Certain genes corresponding to the formation of vitamins and 
co-factors were noted as non-essential as they would be provided to the cell by the medium. 
Changes in these conditions, such as cells grown with minimal media, would therefore require 
additional pre-cursor essential genes.  
A considerable benefit to this essential gene prediction model is the ability to quickly 
identify a set of potential drug targets. Due to the ease of our prediction, this method can be used 
to compare data across different genomes. By understanding crucial biochemical pathways and 
products, we could use model to identify species-selective essential genes as drug targets such as 
with our comparison between S. sanguinis and P. gingivalis. By comparing alternative pathways 
or differences in essential components (e.g., LTA versus LPS), we can identify specified 
essential genes. Information garnered from the comparison of experimental data can provide 
insight for our predictive model such as strain-specific essential genes. We aimed to support this 
hypothesis by selecting m-Ddh as a species-selective target for P. gingivalis. When selecting a 
drug target, it must not only be essential for the survival of the pathogen or disease virulence, it 
must possess certain sequence and structural features and three, have assayable activity. As a 
potential drug target, we were able to show through allelic replacement mutagenesis that m-Ddh 
is an essential enzyme. Previous studies comparing sequence and structural data between targets 
and non-targets showed druggable proteins are more likely to be of certain enzyme classes, 
contain more non-polar amino acids and have a lower isoelectric point, indicating molecules 
65 
 
more acidic in nature [189]. Based on these factors, m-Ddh is a “druggable” enzyme with a 
sequence and structural motif that has the ability to be targeted by small-molecules.  
In conclusion, we have developed an accurate method to quickly predict a core set of 
essential genes through the analysis of gene function. While currently our data may not be 
comprehensive, our results demonstrate that this method can accurately be applied to organisms 
lacking experimental data. As genomic data and gene annotation becomes more complete our 
prediction model will also, and we anticipate more biological functions of hypothetical genes 
will be discovered with the advances of genome research. Further experimental data can also 
narrow the function of those experimental essential hypothetical genes down to the three basic 
biological categories that will increase discovery of gene functions. Additionally, more extensive 
studies can refine our prediction of key differences in essential genes between organisms. For 
example, many genes involved in fatty acid biosynthesis are essential for Bacillus subtilis and 
Escherichia coli, but the pathway is incomplete in Mycobacterium genitalium, indicating the 
product can be provided or is not essential [157]. This will ultimately facilitate our knowledge of 
essential genes. Overall, our study verifies the validity of our previous findings and by applying 
this to P. gingivalis we were able to identify m-Ddh as an essential and “druggable” target for the 
treatment of periodontal disease. 
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Combinational Computer-based Drug Discovery to Identify Small-
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Background 
Historically, antimicrobial drug discovery involved high-throughput screening of thousands of 
compounds for inhibitory activity, followed by secondary assays to identify the mechanism of 
action [97, 194]. Unfortunately, this was time consuming and costly, requiring on average 15 
years and $800 million [96, 195]. Coupled with a low success rate, this investment prompted a 
decline in antibiotic research by pharmaceutical companies, leading to a lack of new and 
effective drugs entering the market [126, 194]. However, with resistance and re-emerging 
pathogens on the rise, new approaches in drug development are critical for the future of 
antibiotics.  
Recent advances in genomics, structural biology and computational chemistry have 
provided alternative strategies to traditional methods, giving rise to rational drug design [196]. 
The principle of rational drug discovery involves identifying or designing compounds based on 
the target’s biological features. Consequently, the validation of a potential target is an important 
first step. We have previously demonstrated the understanding of essential gene functions can 
allow for the rapid prediction of essential genes as potential antimicrobial targets [139]. This 
understanding coupled with the knowledge of alternative pathways and differing metabolic 
requirements can be used to identify unique or species-limited gene targets. With a validated 
target, computer-based drug discovery (CBDD) can be a rapid, efficient and inexpensive way to 
identify and obtain a selection of potential antimicrobial compounds.  
The use of a combinational CBDD approach (i.e., pharmacophore model, structure-based 
virtual screening (SBVS) and molecular docking/scoring) has been shown to be advantageous to 
the drug discovery process in many systemic disease studies, increasing their hit and success rate 
[197-199]. Due to the increasing access of essential genes (i.e. the DEG) [163] and protein 
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crystal structure data (i.e. PDB) [200] it has recently begun to be applied to antimicrobial 
research. A previous study in M. tuberculosis strain H37Rv successfully employed a multi-step 
screening strategy, combining modeling, SBVS and docking to identify a potent inhibitor against 
MtCM, a chorismate mutase [201]. Using a pharmacophore model we can generate a virtual 
description of molecular features essential to the desired protein-ligand interaction [202] based 
on observed experimental or in silico interactions [203]. This pharmacophore model can then be 
used for SBVS, which can replace costly and time-consuming experimental HTS assays. For 
SBVS a database with the structural data of millions of compounds is screened against the target 
protein to identify those that fit within the defined features and molecular docking is used to 
calculate and rank the binding mode for the select ligands within a defined region. Docking and 
scoring is a crucial step in CBDD. By defining an ideal pose, docking can aid in minimizing 
false positives prior to experimental studies and later can be integral in structure optimization 
[202]. However, evaluation of the optimal docking pose can vary based on the specific program 
and algorithm. For example, Goldscore uses a force-field method (summation of van der Waals 
and electrostatic interactions) [204] compared to CHEMPLP which utilizes empirical free energy 
scoring (enumeration of various types of interactions) [205]. To minimize the potential bias, 
studies suggest rescoring with different algorithms to determine the optimal binding 
confirmation [202]. As an additional means to evaluate the protein-ligand interaction, the free 
energy for optimal binding position can be predicted. HINT (Hydropathic INTeractions), 
developed by Kellogg and Abraham [206], is an empirical force field based on experimental 
measurements of the small molecule partition coefficient, Log Po/w. Since Log Po/w is 
thermodynamically related to free energy, the HINT score corresponds to the free energy of 
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intermolecular binding interactions. The combination of these approaches can provide a 
promising start for a novel antimicrobial drug discovery project.  
We aimed to use periodontal disease and the keystone pathogen, P. gingivalis as an 
exploratory model for pathogen-specific drug targeting. We identified m-Ddh from P. gingivalis 
as a species-selective, essential and druggable target. The m-Ddh crystal structure from P. 
gingivalis (PDB ID: 3BIO) [207] was determined as part of the Protein Structure Initiative in 
2007 [207, 208] allowing us to apply a combinational CBDD strategy to identify small-molecule 
inhibitors. In this study, we generated a pharmacophore model based on the natural substrate and 
previous m-Ddh inhibitor studies from B. subtilus and C. glutamicum [209]. We go on to adopt a 
HTS virtual screening method utilizing the ZINC drug-like database of commercially available 
chemicals to identify small-molecule inhibitors. Finally, we docked and scored the HTS results 
to identify a subset of high-ranking compounds as the initial steps in developing a novel strategy 
for antibiotic drug discovery.   
 
Materials and Methods 
Molecular modeling. 
Protein structure. The structure of meso-diaminopimelate dehydrogenase (oxidoreductase, 
Gfo/Idh/MocA family member) from P. gingivalis strain W83, was crystallized as part of the 
National Institute of Health-National Institute of General Medical Sciences (NIH-NIGMS) 
sponsored Protein Structure Initiative (http://www. nigms.nih.gov/Initiatives/PSI/) [210, 211] 
and was solved at a resolution of 1.80 Å. The crystal structure data was downloaded from the 
Protein Data Bank (PDB ID: 3BIO) [207] and applied in our study. The binding site was 
identified by sequence homology to the ortholog in C. glutamicum, whose crystal structure was 
70 
 
previously determined in a complex with the substrate, meso-diaminopimelate (m-DAP), in the 
binding pocket (PDB ID: 2DAP) [190]. Using Sybyl X.1 (Tripos, St. Louis, MO), the protein 
was prepared for virtual screening and docking studies by extracting water molecules and co-
crystallized ligands and deleting one of the two monomers. The pKa values of the amino acid 
residues within the binding pocket were predicted and the appropriate ionization states were 
assigned in SYBYL for a pH 10.5 based on the conditions of the in vitro enzymatic experimental 
assay. Appropriate atom types were assigned, hydrogens were added and the protein was 
minimized with Sybyl’s Tripos force field.  
Structure-based virtual screening. Virtual screening was performed with the UNITY module 
within the Sybyl-X molecular modeling program Unity uses a directed tweak algorithm [212] to 
simulate molecular flexibility while screening small molecules. The binding pocket of m-Ddh 
was used as the target site, by constructing a variety of queries based on the pocket’s properties. 
Over 9 million small molecules were screened in silico from ZINC [213] drug-like databases 
(http://www.zinc.docking.org).  
Molecular docking. Docking and two-step scoring was used to evaluate the results of virtual 
screening. By visually inspecting and filtering the UNITY hits, we selected the top 132 small-
molecule compounds for further computational analysis. We used GOLD (Genetic Optimization 
Ligand Docking) docking program v5.2) [204], targeting the binding site of in m-Ddh. A sphere 
with radius of 12 Å from Arg183 was set as the docking region. This allowed for the inclusion of 
all residues expected to be within the binding site. The protein model was prepared for docking 
as described above. Conformational flexibility was allowed for the small molecules. We allowed 
for 50 GA (Genetic Algorithms) runs with a distance of 1 Å between clusters. The 132 
compounds selected from our virtual screening hits were docked by GOLD, ranked by Goldscore 
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and then re-ranked by the CHEMPLP as implemented in GOLD. All docked compounds were 
then scored in a second pass by HINT (Hydropathic INTeractions) [214]. The binding mode 
corresponding to the highest-ranking HINT score for each compound was chosen as the best and 
most likely conformation for that compound. From these 132 compounds, the top 30% of the 
best-scored, structurally diverse compounds as ranked by HINT were re-docked and minimized 
with 10,000 iterations within the m-Ddh binding site. Finally, out of forty top scored small 
molecules, 11 compounds were commercially available and were purchased for assay. All 
images were generated in Pymol (http://www.pymol.org).   
Cloning, expression and purification of m-Ddh. The amino acid sequence of m-Ddh from P. 
gingivalis was codon-optimized for expression in E. coli cells, synthesized and cloned into a 
pUC57 vector by GenScript (Piscataway, NJ). To introduce the 6×-HIS tag to the C-terminal end 
of the gene, the plasmid was digested at NdeI and NotI restriction sites. The digested fragments 
were loaded onto a 1% agarose gel and purified using MinElute® Gel Extraction kit (Qiagen, 
Valencia, CA). The purified DNA insert was ligated into a NdeI- and NotI-digested pET-21a (+) 
vector (Merck Millipore, Billerica, MA) by T4 DNA ligase (New England Biolabs, Ipswich, 
MA), yielding the expression plasmid pET-Ddh. The plasmids containing the DNA construct 
were isolated using QIAprep® Spin Miniprep plasmid (Qiagen, Valencia, CA) and sequenced at 
VCU Nucleic Acids Research Facilities (Richmond, VA).  
The pET-Ddh plasmid was introduced into E. coli BL21 (DE3) pLysS (BioLine, 
Taunton, MA) and grown overnight in auto-inducing media ZYP5052 containing 100 µg/ml 
ampicillin at 37 ˚C. For purification, cells were disrupted by Emulsiflex C3 high pressure 
emulsifier (Avestin, Ottawa, Canada). Soluble protein was collected and separated from cell 
debris by centrifugation (20, 000 × g for 20 mins at 4 ˚C). The resulting supernatant was loaded 
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onto a NTA-Ni2+ affinity column (Qiagen) pre-equilibrated with running buffer (25 mM Tris, 
300 mM NaCl, 10 mM imidazole, pH 8.0). Unbound protein was washed off with wash buffer 
(25 mM Tris, 300 mM NaCl, 10 mM imidazole, pH 8.0) and chelated protein was eluted off with 
elution buffer (25 mM Tris, 300 mM NaCl, 100 mM imidazole, pH 8.0). Protein concentration 
was calculated based off of absorbance at 280 nm. 
Molecular mass analysis of purified m-Ddh. The enzyme was examined by 12.5% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) stained with Coomassie Blue 
G-250 (Bio-Rad, Hercules, CA). Samples were boiled in 2X Laemmli buffer (4% SDS, 10% β-
mercaptoethanol, 20% glycerol, 0.125M Tris-HCl, 0.004% bromophenol blue).  
 The molecular weight of the native enzyme was determined by gel filtration 
chromatography. Gel filtration was carried out using an Äkta Pure Protein Purification System 
(GE Healthcare, USA) with a 1 ml injection loop. The column was calibrated using Gel filtration 
protein standards of molecular weights ranging from 12,000 – 200,000 Da: standards 1, β-
amylase (200 kDa) and cytochrome c (12.4 kDa); standards 2, alcohol dehydrogenase (150 kDa) 
and carbonic anhydrase (29 kDa); standards 3, albumin (66 kDa). 500 l of a 3.2 mg/ml purified 
protein was run through a Superdex 75 10/300 GL column (GE Healthcare, USA) at an elution 
rate of .5 ml/min with a 25 mM Tris-HCl, 300 mM NaCl, 100 mM imidazole buffer (pH 7.5) 
elution buffer. Fractions of 1ml volume were collected.  Fractions were then analysed by 
spectrophotometry. Protein size was calculated by standard curve of molecular mass vs. Ve 
(elution volume)/Vo (void volume) for each protein standard. 
m-Ddh kinetic assay. The enzymatic activity for m-Ddh was determined by observing the 
standard oxidative deamination reaction of the substrate meso-diaminopimelate [215]. The 
reaction contained 400 µM of meso-diaminopimelate (Sigma-Aldrich, St. Louis, MO), 180 µM 
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NADP+ (Sigma-Aldrich, St. Louis, MO), 200 mM glycine-KCl-KOH buffer (pH 10.5), and the 
enzyme in a final volume of 1 ml. The reaction was initiated with the addition of NADP+. The 
reaction velocity was calculated from the increase in absorbance at 340 nm, 
spectrophotometrically monitored at 25 ˚C, where one unit of enzyme was defined as the amount 
of enzyme catalyzing the formation of 1 mmol of NADPH per min. 
Determination of kinetic parameters. Initial velocity measurements for m-DAP and NADP+ 
were determined at 25 ˚C in a similar reaction for the standard oxidative deamination reaction 
assay. The reaction contained 200 mM glycine-KCl-KOH buffer (pH 10.5) with m-DAP as the 
variable substrate with concentrations between 0.001 mM and 1 mM and NADP+ held constant 
at a saturating concentration of 0.5 mM or NADP+ as the variable substrate with concentrations 
between 0.01 mM to 1 mM and m-DAP held constant at 0.5 mM. Km and Vmax values were 
determined through non-linear fitting. All assays were performed in triplicates and non-linear 
fitting Michaelis-Menten data were calculated from Graphpad Prism v5.04 (Graphpad, San 
Diego, CA).  
Mutagenesis of m-Ddh. For site directed mutagenesis, pET-Ddh plasmid was used as a template 
for single residue site-directed mutagenesis of m-Ddh (R183Y, R183K, D124E and D124A). The 
phosphorylated primer set for each mutant was as follows. Forward R183Y: 5’- ACG GGT GTG 
CAT CGT TAT ATG GTC TAT GTG GAA-3’ and Reverse R183Y: 5’- TTC CAC ATA GAC 
CAT ATA ACG ATG CAC ACC CGT-3’; Forward R183K: 5’- ACG GGT GTG CAT CGT 
AAA ATG GTC TAT GTG GAA -3’ and Reverse R183K 5’- TTC CAC ATA GAC CAT TTT 
ACG ATG CAC ACC CGT-3’; Forward D124E: 5’- C GCA TCA GGC TGG GAA CCG GGT 
AGT GAT TCC-3’ and Reverse D124E: 5’- GGA ATC ACT ACC CGG TTC CCA GCC TGA 
TGC G -3’; Forward D124A: 5’- ATC AGG CTG GGC GCC GGG TAG TG -3’ and Reverse 
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D124A 5’- GCG ATA ACC GCA GCT GCA -3’. All PCR reactions were performed with an 
initial denature of 98 ˚C for 30 sec, 25 cycles of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 2 
min 45 sec and a final extension of 72 ˚C for 7 min. PCR products were digested with 1 U of 
DpnI (New England Biolabs, Ipswich, MA) at 37 °C for 1 h and inactivated for 20 min at 80 °C. 
The plasmids containing the mutation were sequenced at VCU Nucleic Acids Research Facilities 
(Richmond, VA). The final product was used to transform into E. coli DH5α T1 competent cells. 
Phusion High-Fidelity Taq DNA polymerase (New England Biolabs, Ipswich, MA) was used in 
all reactions. Mutants were transformed, expressed and purified as previously described for WT. 
 
Results 
In silico analysis of m-Ddh structure and function. The enzyme catalyzes the NADP+ 
dependent oxidative deamination of m-DAP (Fig. 10). The reaction is reversible and the 
biologically favored reaction involves the NADPH dependent conversion of L-2,3,4,5-THDP to 
m-DAP by reductive animation. During this reaction L-2,3,4,5-THDP first has a spontaneous 
ring opening to produce L-α-amino--ketopimelate. L-α-amino--ketopimelate catalyzed by m-
Ddh generates an imine intermediate before yielding m-DAP. Crystal structure data suggests the 
protein is similar to previously studied m-Ddhs [182, 216-218]. It is a homodimer and sequence 
analysis indicates it consists of three main domains: a NADP+-binding domain which 
corresponds to the conserved GXGXXG sequence found within the N-terminal βαβ-protein fold 
[219], a dimerization domain and an oxidoreductase domain (Fig. 11). Studies in C. glutamicum 
and B. sphearicus show that m-Ddh has a strict specificity for the D-amino acid center of m-DAP 
being placed near the NADP(H) domain [220-222].  
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Figure 10. Schematic for the m-Ddh catalyzed biochemical reaction. 
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 To assess the binding model of the natural substrate within the protein pocket we docked 
m-DAP (Fig. 12). The protein was prepared as described in “Materials and Methods” and we 
used GOLD docking program v5.2, selecting the 9 a.a. residues previously predicted to be the 
binding site as the area of the docking region. m-DAP binds within a deep groove situated so that 
the two carboxylate groups face the protein side allowing for hydrogen bond interactions 
(Arg183, Thr173, Met154 and Gly155). The two amine groups face away from the protein 
allowing for potential solvent interactions. The positioning places the D-amino acid center near 
the NADP+ binding site to allow for the hydrogen exchange and the enzymatic reaction to occur. 
This binding mode corresponded to what has been observed in crystal data studies [190, 220].  
In vitro analysis of m-Ddh structure and function. To first confirm the structural and 
functional in silico analysis of m-Ddh, we synthesized the gene and expressed it in E. coli. The 
gene sequence encoding for P. gingivalis m-Ddh was codon-optimized and cloned into a T7 
pET-21a (+) expression vector carrying a C-terminal 6x HIS tag. The protein was isolated 
following the expression and purification described in “Materials and Methods”. The protein is 
301 a.a. residues with a calculated molecular weight of 32 kDa, corresponding to the migration 
of the monomeric structure on SDS-PAGE (Appendix, Supp. Fig. 2a). The crystallized structure 
of m-Ddh from P. gingivalis indicated that the enzyme exists as a homodimer, the native 
molecular weight was determined by gel filtration chromatography where two prominent peaks 
eluted similarly to standard 3 (Appendix, Supp. Fig. 2b) at a calculated size of 66 kDa, 
demonstrating that the active enzyme exists as a dimer. 
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Figure 11. Structural domains of m-Ddh from P. gingivalis.  
Dimer (top) and monomer (bottom) structure of m-Ddh from P. gingivalis. Structure consists of three 
main domains which are highlighted by different colors. The substrate or oxidoreductase domain 
(yellow), the dimerization domain (green) and the NAD(P) domain (blue). The NADP domain found in 
the N-terminal sequence of m-Ddh corresponds to the conserved GXGXXG sequence within a 
structural motif. 3D structure of m-Ddh was generated in Pymol (http://www.pymol.org). m-DAP docked 
within the binding pocket is shown in pink.  
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Figure 12. Molecular docking analysis of m-DAP binding model.  
GOLD was used to dock the natural substrate, m-DAP into the predicted binding pocket of m-Ddh. The 
optimal binding model determined by HINT score is displayed above (pink). Binding position of m-DAP 
from previous crystal data studies (PDB ID: 2DAP) is overlaid with predicted docking model (yellow) to 
show similar binding. NADP+ docked in its binding pocket is shown below to display the positioning for 
the hydrogen exchange and the enzymatic reaction. Key residues for intermolecular interactions are 
labeled, displayed as ball and sticks and colored corresponding to atom type. Hydrogens were omitted for 
clarity. Potential hydrogen bonding interactions between m-Ddh and a.a. residues are shown by yellow 
dashed lines.  
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 We next examined the Michaelis kinetics to evaluate the activity of the enzyme and 
determine the kinetic parameters for the oxidative deamination of m-DAP. This reaction is 
spectrophotometrically observable at 340 nm. This allowed for the development of a standard 
screening assay, monitoring the reduction of NADP+ to NADPH. Analysis of the initial velocity 
showed typical Michaelis-Menten kinetics (Fig. 13). The apparent Km and Vmax for m-DAP was 
determined to be 370 M and 130 nmol sec-1 and 60 M and 92 nmol sec-1 for NADP+ (Fig. 13) 
respectively. 
 Docking studies indicated that the carboxylate groups were essential for the binding 
through hydrogen bonding interaction. To verify this we selected Arg183 to mutate with a 
favored residue substitution or an un-favored substitution (Table 3; Fig. 14a). An Arg mutation 
to an un-favored substitution (R183Y) resulted in a significant decrease in substrate affinity (35-
fold increase in the apparent Km) compared to WT but retained similar catalytic efficiency. This 
was in contrast to the favored Arg substitution (R183K) which maintained similar Km and 
Kcat/Km values as the WT. Comparison of these two mutants with the WT docking showed a loss 
in a favorable hydrogen bonding between R183 and m-DAP during the Y183 mutation which led 
to a decrease in the calculated HINT interaction. Mutant R183K had a similar pose as WT, 
reflected by a strong HINT interaction between the carboxylate group of m-DAP and the amine 
group from K183. Asp124 is positioned within the protein for both NADP+ and m-DAP 
interaction. A favored mutation (D124E) resulted in a slight increase in substrate affinity (2.7-
fold decrease in the apparent Km) and an increase in catalytic efficiency. In contrast, the D124A 
mutation had a dramatic change in both the apparent Km and the catalytic efficiency resulting in 
almost no measurable activity (Table 3; Fig. 14b). Docking showed similar potential hydrogen  
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Figure 13. Kinetic analysis of purified m-Ddh from P. gingivalis strain W83. 
Characterization of kinetic properties of m-Ddh. Oxidative deamination reactions were 
performed in the presence of increasing concentrations of (a) m-DAP as the variable substrate 
with NADP+ fixed at a saturating concentration or (b) NADP+ as the variable substrate and m-
DAP held constant. Km and Vmax values were determined through non-linear fitting.  
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Table 3. Kinetic analysis of m-Ddh mutants. 
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Figure 14. Site-directed mutagenesis of binding pocket. 
GOLD was used to dock the natural substrate, m-DAP into m-Ddh with single a.a. substitutions of the 
predicted binding pocket. The optimal binding model is displayed above. (a) Arg183 mutated to R183Y 
left and R183K right with m-DAP docked. (b) Asp124 mutated to D124E left and D124A right with m-
DAP docked. Key residues for intermolecular interactions are displayed as ball and sticks and colored 
corresponding to atom type. Mutated residues are labeled in red. The optimal m-DAP docked for WT m-
Ddh is shown in pink to highlight changes in binding confirmation. Changes in potential hydrogen 
bonding interactions that would affect activity is displayed as a dashed yellow lines. Hydrogens were 
omitted for clarity. 
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bonding for the D124E mutant, however there was a more favorable acid-base interaction 
compared to WT. Conversely, D124A showed a slightly unfavorable base-base interaction 
between the carboxylate group of m-DAP and the backbone of Asp.  
Generation of pharmacophore model.  To identify a binding model for inhibition, we searched 
the literature for known inhibitors. Unsaturated analogues of m-DAP, containing a planar α-
carbon and lacking the active D-amino acid amine center of m-DAP have been shown to be 
strong inhibitors of m-Ddh isolated from Bacillus sphaericus and C. glutamicum [209]. It was 
assumed the analogue inhibitors bind in manner opposite to that of the substrate; thus, the non-
reactive L-amino acid center is positioned near the C-4 position of the co-substrate NADP+. This 
would prevent the oxidation reaction and hydride exchange that normally would occur between 
the substrate and co-substrate. We obtained two of these previously reported compounds; testing 
in vitro showed dose-dependent inhibition against m-DAP from P. gingivalis. 
 The X-ray crystal structure was modeled and the unsaturated analogue inhibitors 
(Compounds 1 – 3) as well as the m-DAP substrate were docked into the m-Ddh binding pocket 
to identify the features that should be important for inhibitor interactions (Fig. 15a). The docking 
model which best fit the expected in vitro interaction and displayed high docking scores was 
used to generate a pharmacophore model. Based on the best ranking interaction, the 
pharmacophore model focused on four features that were shared between the inhibitors and 
substrate: 1) a hydrophobic region complementary to amino acid residues Trp123 and Phe148; 2) 
a ligand donor atom complementary to residues Asp94 and Asp124; 3) a negative (acceptor) 
center complementary to the side chain of residue Ser153 and the backbone of residues Met154 
and Gly155; and 4) a negative (acceptor) center complementary to the side chains of residues 
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Figure 15. Generation of pharmacophore model. 
(a) Structure of m-DAP and inhibitor analogs that were previously shown to be active against m-Ddh in 
C. glutamicum and B. sphaericus. (b) Compounds docked into m-Ddh binding site and conserved 
interactions were identified. (c) Pharmacophore model with selected core features for inhibitor 
identification during virtual screen. The model focused on four features: first, a hydrophobic region 
complementary to amino acid residues Trp123 and Phe148 (green), second, a ligand donor atom 
complementary to residues Asp94 and Asp124 (purple), third, a negative center complementary to the 
side chain of residue Ser153 and the backbone of residues Met154 and Gly155 (red) and fourth, a 
negative center complementary to the side chain of residues Arg183 and Thr173 (red). The interaction 
was also restricted for an area 12Å in distance for Arg183. Key residues are labeled, displayed as ball and 
sticks and colored corresponding to atom type. Hydrogens were omitted for clarity.   
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Arg183 and Thr173. The interaction was also restricted to a sphere of radius 12 Å centered 
around Arg183. This was because from our docking model Arg183 was seen to form hydrogen 
bonds with the carboxylate groups of the substrate analogues and site-directed mutagenesis 
decreased the substrate-protein binding affinity by 32-fold.   
High-throughput virtual screening for identification of small-molecule inhibitors. The 
pharmacophore model shown in Figure 15b was used in a high-throughput virtual screen of the 
ZINC 3D database to identify small-molecule inhibitors that would fit the query constructed 
from the pharmacophore. ZINC (Zinc Is Not Commercial) is a publicly available listing of 
molecules that are reportedly available for purchase, organized in a manner appropriate for 
virtual screening studies. In simple terms, a compound was classified as a hit if it fit all of the 
features defined as mandatory in the model. The screening of more than 9 million compounds 
within the ZINC database resulted in more than several hundred hits. Since the goal of virtual 
screening is to identify unique compounds and scaffolds that have the potential to be developed 
into active inhibitors, a filter was applied to remove compounds within the hit list too structurally 
similar to one another. The resulting list was then filtered for drug likeness (i.e., with algorithms 
based on Lipinski’s Rule of Five [188]) to remove compounds and scaffolds that were unlikely 
to have reasonable physiochemical properties.   
Molecular docking and scoring of small-molecule inhibitors. Compounds passing through 
these filters were then docked to the binding site of m-Ddh with GOLD (Genetic Optimization of 
Ligand Docking) program to predict their binding affinities and to assess the modeled 
compound-protein interactions. Prediction of the best fit binding model of each compound, again 
within 12 Å of Arg183, was determined and scored by Goldscore. The models with top docking 
scores were re-docked to the binding site with the same docking parameters and rescored by 
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CHEMPLP. A filter based on binding pose was applied and compounds that interacted 
favorably, mostly via hydrogen bond, with the key residue Arg183 were identified. This filter 
yielded 132 hits, which were then scored by the HINT force field. The binding mode 
corresponding to the highest HINT score for each compound was then re-docked and minimized 
within the m-Ddh binding site. From these 132 compounds, the top 30% of the best HINT-
scored, structurally diverse compounds were set-aside as the 48 final hits. Finally, samples of the  
commercially available compounds in this group were purchased for future screening assays. 
The HINT scores and compound structures of each of these 11 compounds (4 – 14) are shown in 
Table 4. 
In silico analysis of binding confirmations. The optimal binding pose for the six top ranking 
compounds determined by HINT score are shown in Figure 16. The protein-inhibitor interaction 
involved potential hydrogen bonding interactions with the backbone for Met154, Ser153 and 
Gly155. The majority of the compounds possessed aromatic structures forming favorable 
hydrophobic interactions with Phe148 or Trp123. The sulfonamide functional group on 
compound 4, 5 and 6 show potential hydrogen bonds with Arg183 and Thr173. Due to distance 
few compounds show potential hydrogen bonding with the Asp functional group. The exception 
was compound 10 which lost hydrogen bonding between Arg183 and Thr173 to gain favorable 
hydrogen bonding interactions with Asp93. Overall, these compounds maintained the desired 
interaction determined through the pharmacophore model. 
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Table 4. 2D structures and scoring of top-ranking compounds 
 Structure HINT 
Compound 4 
 
3112 
Compound 5 
 
3014 
Compound 6 
 
2876 
Compound 7 
 
2095 
Compound 8 
 
4379 
94 
 
Compound 9 
 
2569 
Compound 10 
 
4274 
Compound 11 
 
2344 
Compound 12 
 
1989 
Compound 13 
 
4190 
Compound 14 
 
1692 
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Figure 16. Optimal binding mode for top-ranking compounds. 
Optimal binding model for the top-ranking compounds determined through HINT are shown above (see 
Table 4). Key residues are displayed as ball and sticks and colored corresponding to atom type. Residues 
labeled in the bottom middle figure correspond to all figures. Hydrogens were omitted for clarity. 
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Discussion 
Novel therapeutics have not kept paced with the need to overcome antibiotic resistance and fight 
new and re-emerging pathogens. Traditional methods principally relied on empirical screening, 
screening large numbers of compounds for whole-cell activity, flushing out the mechanism of 
action and verifying the feasibility of the target later. This resulted in a costly and time-
consuming endeavor that was especially discouraging for small startups and academia which 
lack the resources of larger pharmaceutical companies. In addition, as the ‘golden era’ of 
antibiotic discovery waned, this approach proved ineffective. However, steady advances in 
computational chemistry, protein chemistry and genomics have resulted in successful drug 
discovery through CBDD for systemic diseases such as cancer [202]. Utilizing a combination of 
CBDD techniques, a better understanding of a target can be gained, the properties essential for 
the activity or inhibition assessed and a diverse set of inhibitors identified.  
 In this study, we aimed to present a rationalized approach to antibiotic drug discovery. 
We employed a combinational CBDD approach which incorporated pharmacophore models, 
SBVS and molecular docking. Ultimately screening more than 9 million small-molecule 
compounds to identify potential inhibitors against P. gingivalis and utilize a novel approach in 
antimicrobial drug discovery. By applying this method to the Gram-negative periodontal 
pathogen, P. gingivalis, we showed that: 1) we can accurately assess the structure/function of our 
target through computer-based molecular modeling; 2) we can identify key molecular features 
for inhibitor screening; and 3) utilizing several CBDD techniques in parallel can lead to a rapid 
selection of inhibitors. 
The crystal structure data of m-Ddh was used to first examine the structure and related 
function of the enzyme. The enzyme is an active homodimer that binds m-DAP and NADP+ 
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within close proximity at the N-terminus of the protein. It has been shown to have strict 
specificity for the substrate which must bind in a certain orientation. This would allow for 
specific hydrogen bonding interactions with the carboxylate groups of m-DAP. It also positions 
the catalytically active amine group near the NADP+ moiety. As m-Ddh from P. gingivalis has 
not been characterized in vitro, we expressed and purified the protein from E. coli. Gel filtration 
analysis confirmed the assumed tertiary confirmation consistent with other characterized m-
Ddhs. Previous studies of m-Ddh and its role in lysine biosynthesis have focused on the enzyme 
from Corynebacterium [190], Bacillus [184], and Ureibacillus [217]. However, prior to our 
study there was no enzymatic data on m-Ddh in P. gingivialis available. Therefore, we 
determined the kinetic properties through the assessment of the enzyme assay. Analysis of the 
kinetic data showed a Km value of 370 M with a Vmax of 130.1 nmol sec-1 for the substrate m-
DAP and a Km of 60 M with a Vmax of 91.95 nmol sec-1 for NADP+. We next used site-directed 
mutagenesis to further evaluate the in silico interaction. The side chain of Arg183 was shown to 
form hydrogen bonds within the active site. Mutation of Arg183 to Tyr was still catalytically 
active but showed a large decrease in substrate binding compared to the WT. This may indicate 
the replacement of Arg to the aromatic structure of Tyr may prohibit m-DAP access into the full 
length of the active site but still allows for the enzymatic reaction near the D-amino center. D124 
is found within the overlap between the substrate and co-substrate binding sites. Asp residues 
within active sites are known to form stabilizing hydrogen bonds through salt bridges [223]. The 
Ala substitution left the enzyme almost inactive. However a Glu substitution, which is similar to 
Asp in structure and function, slightly increased the binding and efficiency. This could indicate 
D124 may play an essential role in m-Ddh protein stabilization.  
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By analyzing the binding model of substrate analogue inhibitors we were able to define a 
pharmacophore model with consistent features between three inhibitors and the substrate. Our 
four key features mainly focused on the potential hydrogen bonding interactions. First identified 
was a hydrophobic region from the aromatic residues Trp123 and Phe148. This interaction would 
allow for another ring within that region and lead to potential hydrophobic stacking interactions.  
The second feature, a ligand donor atom complementary to residues Asp94 and Asp124 would 
allow for hydrogen bonding between the carbonyl oxygen groups. The third feature is a negative 
(acceptor) center complementary to the side chain of residue Ser153 and the backbone of 
residues Met154 and Gly155. The backbone of these residues would allow for potential 
hydrogen bonding with the ligand acting as a hydrogen acceptor. The last feature was a negative 
(acceptor) center complementary to the side chains of residues Arg183 and Thr173. This feature 
is similar to feature three but involves the side chains for potential bonding. This characterization 
allowed for the application of a rational HTS strategy utilizing the ZINC compound database. 
Compounds identified were then subjected to docking analysis through GOLD and two distinct 
scoring approaches. This resulted in more than 100 compounds. Finally a subset of the 
commercially available compounds which were computationally determined to be the best fit 
were selected for future in vitro analysis.  
In conclusion, we have successfully applied a CBDD method to identify a select group of 
structurally diverse small-molecule compounds against m-Ddh. While currently this data is 
preliminary, our results demonstrate that this multifactorial method can accurately be applied to 
antimicrobial drug discovery and due to the feasibility, can be used across a variety of infectious 
pathogens. In addition, the rational selection and preliminary in silico screening should lead to a 
higher success rate than traditional trial and error experimental screening. This study may also 
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present a better understanding of our validated target. Through computational modeling we can 
further study the structure of the protein. This is important, as molecular features correspond to 
the activity of the protein and by understanding these features a compound can then be selected 
or designed to interact against these features. Ultimately, this may result in a more in-depth 
pharmacophore model, improved HTS drug screening or structural optimization of active 
inhibitors. Overall, our study presents the rationale for this approach and by applying this to P. 
gingivalis we were able to identify potential inhibitors for the treatment of periodontal disease. 
Coupled with further experimental data we can verify our computational analysis and this should 
aid in the progression of an antimicrobial drug discovery model. 
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Chapter Three  
In vitro Characterization of Small-Molecule Inhibitors against meso-
diaminopimelate dehydrogenase 
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Background 
Undoubtedly, CBDD is an exceptional way to identify a set of inhibitors against a specific target. 
The rational assessment of potential interactions allows for the selection of small molecules with 
a higher probability of binding, thereby increasing the efficiency of HTS [202]. However, their 
activity is based on computational algorithms and is therefore theoretical. It does not provide 
information on the potency, pharmacokinetics or cytotoxicity. Before inhibitors identified in this 
manner can progress into potential antimicrobials, it is necessary to evaluate the defined activity 
through an in vitro screening phase. Primarily, this consists of two general biochemical 
methodologies: target-based to assess protein-inhibitor interaction and cell-based to screen for 
whole-cell growth effects [224].   
 Target-based screening assays are used to verify the inhibitor binds the identified target 
and has a significant effect on its activity. First, it is important the target can be isolated, 
characterized and a suitable assay can to be developed that is simple and cost-effective while 
being sensitive enough to detect changes in activity [122]. This is to ensure that the assay is able 
to screen a large amount of small molecules and the results are reproducible. With our target, m-
Ddh, purified and enzymatically characterized, we determined a standard enzymatic assay for 
screening. The reduction of the co-factor NADP+ to NADPH is monitored at 340 nm by 
spectrophotometric analysis and the rate of that reaction determined. Inhibition can then be 
defined by the corresponding changes in the enzymatic rate. This screening strategy is similar to 
the HTS performed by GSK for the identification of inhibitors against two enoyl-ACP reductase 
enzymes, FabI and FabK [126]. By monitoring the consumption of NAD(P)H, an inhibitor 
displaying slight in vitro activity was identified and later optimized for whole-cell activity [225, 
226]. Observed target inhibition is used to relate potential pharmacodynamics and 
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pharmacokinetics of the inhibitor by constructing a dose-response curve. This is used to observe 
the effect that different concentrations have on the enzyme activity, generating the concentration 
at which half the enzyme activity is inhibited (IC50) [227]. The IC50 allows for the assumption 
that the inhibition is directly correlated to the inhibitor (non-toxic). Further target-based assays 
during this stage lead into target-related mechanism of action studies, such as defining the 
inhibition pattern and binding affinity. Additionally, this data provides the relative inhibitor 
activity and combined with structural analysis outlines the initial SAR studies [228]. Ultimately, 
this can be used to understand which parts of the ligand can be altered to improve activity or the 
pharmacodynamics.  
One of the most essential properties of an antibiotic is the ability to cross the membrane 
and exert a biological effect on the cell. However, inhibitors that show activity against a target 
may not possess the optimal structural properties for whole cell activity. Whole-cell based assays 
are used to determine whether a small molecule possess antimicrobial properties. MICs, defined 
as the lowest concentration that inhibits cell growth, are typically used as a cell-based method to 
relate inhibition to activity. However, it is important to connect whole-cell activity with a target’s 
inhibition or in other words verify the MoA [229]. This can involve the alteration of the intended 
target such as over- or underexpression of the target [230], transcriptional analysis of inhibitor 
treated cells [231] and phenotypic profiling of associated changes in the cell [232]. This can be 
supported with secondary screenings across multiple species. If screening against a species that 
lacks the target of interest results in significantly higher MICs, it can be assumed that the small 
molecule has a specified MoA. This has been successfully applied in drug studies involving 
FabI/FabL [233], which used over-expresssion and knockout mutants to discover a novel enoyl-
ACP reductase functional protein sensitive to triclosan. 
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 Drug discovery is a multi-step approach. Computational methods can rationally select 
small-molecules, reducing associated cost and time investments of HTS empirical screening. 
However, in vitro experimental screening cannot be eliminated from the process because it is 
necessary to identify lead inhibitors for drug development. We previously identified more than 
100 small molecules through a CBDD method and purchased 11 of the commercially available, 
top-ranking compounds for further analysis. In this study, we aimed to determine the in vitro 
activity of the small molecules proposed to target m-Ddh in P. gingivalis. Applying a two-step 
biochemical screening approach, we used our standard enzymatic assay to evaluate target-
inhibitor interaction followed by whole-cell based assays for the assessment of their 
antimicrobial activity. Using biochemical screening as a complement to computational 
approaches provides a comprehensive framework for the initial steps of a drug development 
approach.  
 
Materials and Methods 
Bacterial Strains, plasmids and growth conditions. P. gingivalis strain W83, Prevotella 
intermedia strain 17 and S. sanguinis strain SK36 were all cultured anaerobically (10% CO2, 
10% H2, and 80% N2) at 37 °C in tryptic soy broth (TSB) (Becton Dickinson, Franklin Lakes, 
NJ) supplemented with 1 µg/ml menadione and 5 µg/ml hemin.  
Compounds. The selected small molecules were purchased from Vitas-M Laboratory, Ltd. 
(Moscow, Russia), Molport (Riga, Latvia) and/or eMolecules (La Jolla, CA, USA), which 
reported purities over 90%, analyzed by NMR and/or LC- MS. All compounds were re-
suspended in DMSO (Sigma–Aldrich, St. Louis, MO, USA) prior to use.  
105 
 
Inhibitor screening and determination of IC50 values. A range of concentrations (0 - 3 mM) of 
each small molecule inhibitor were added to the standard reaction and the percent of m-Ddh 
enzymatic inhibition was measured by the kinetic assay previously described. Percent inhibition 
was determined by the formula: 
( 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑛𝑜 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 )–(𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟) 
𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑛𝑜 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟
×  100. The 
concentration of each inhibitor which caused 50% enzymatic inhibition (IC50) was calculated 
using PRISM v6.04 software (Graphpad, San Diego, CA) from three independent experiments. 
Determination of antimicrobial properties. Minimal Inhibitory Concentration (MIC) assays 
were performed using a broth microdilution method [234]. P. gingivalis or P. intermedia cells 
were grown overnight and the following day diluted 1/10 into fresh medium. S. sanguinis cells 
were grown overnight and the following day diluted 1/100 into fresh medium. Cells were 
allowed to grow to mid-log phase (OD600 ≈ 0.5). Inhibitors were serially diluted in 96-well 
microtiter plates (Jet Biofil, Genesee Scientific, San Diego, CA) and an aliquot of the cell 
suspension was added to each well with the inhibitor sample for a final cell count of 1×105 
CFU/ml. Plates were incubated either overnight (S. sanguinis) or five days (P. gingivalis and P. 
intermedia) at 37 ˚C in anaerobic conditions. The MIC was defined as the lowest concentration 
of inhibitor that visually reduced cell growth relative to the controls. 
Minimal bactericidal concentrations (MBC) were determined by plating bacteria from 
wells of the MIC assay that showed no visible growth. Samples were plated on tryptic soy agar 
plates supplemented with 5% sheep blood (Becton, Dickinson, Franklin Lakes, NJ) and 
incubated at 37 ˚C in anaerobic conditions for 7 days. MBC was defined as the lowest 
concentration of inhibitor that resulted in no colony formation/growth.  
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Time-kill assay. P. gingivalis cells were grown overnight and the following day diluted 1/10 
into fresh medium. Cells were allowed to grow to mid-log phase (OD600 ≈ 0.5) then diluted to a 
final cell suspension of 1×105 CFU/ml. Inhibitors were added at a concentration of 5× the MIC 
determined from the 96-well broth microdilution assay. Samples were taken at different time 
intervals (0, 0.25, 0.5, 1, 2, 3, 4, 6 and 24 h) and plated on tryptic soy agar plates supplemented 
with 5% sheep blood (Becton, Dickinson, Franklin Lakes, NJ) using an automated Eddy Jet 
spiral plater (Neutec Group, Farmingdale, NY). Plates were incubated at 37 ˚C in anaerobic 
conditions for 7 days.   
SEM analysis of inhibitors exposed P. gingivalis cells. Untreated or treated P. gingivalis cells 
were deposited onto a 0.1 µm disposable Millipore filter to remove medium, and samples were 
fixed using 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 30 min, followed 
by 1% osmium tetroxide in 0.1 M sodium cacodylate buffer (pH 7.4). Samples embedded in the 
filters were then dehydrated in ethanol followed by hexamethyldisilazane (HMDS) and allowed 
to air dry. The filters were sectioned and mounted onto stubs and coated with gold for three 
minutes (EMS – 550 Automated Sputter Coater, Electron Microscopy Sciences, Hatfield, PA). 
Micrographs were taken at 30,000× total magnification using a Zeiss EVO 50 XVP scanning 
electron microscope (Carl Zeiss, Peabody, MA). 
Analysis of inhibition mechanisms. Kinetic studies were carried out using the standard kinetic 
assay for the oxidative deamination of m-DAP. Reactions were performed in the absence or 
presence of inhibitors (0 - 0.4 mM) with varying concentrations of the substrate m-DAP or co-
substrate NADP+. The mode of inhibition and Ki was determined from non-linear regression 
using PRISM v6.04 software (Graphpad, San Diego, CA) from three independent experiments. 
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The mode of inhibition was graphically visualized with Lineweaver-Burk or Hanes-Woolf plots 
according to Cleland kinetics [235].  
 
Results 
Evaluation of enzymatic inhibition against m-Ddh. The initial screens for the compounds 4 - 
14 were performed by individually adding each one to the assay solution. To identify inhibitors 
with moderate to low activity, the preliminary screening was run at a concentration of 3 mM. 
Enzymatic activity was measured by the standard assay described in “Materials and Methods” 
and the % inhibition was calculated in comparison to the untreated enzymatic rate. This resulted 
in four compounds (4, 5, 6 and 7) that displayed at least 90% inhibition of enzymatic activity. 
The other compounds screened displayed 20% or less. These four compounds were then re-
screened with a minimum of six concentrations to determine the IC50 value (Table 5). The IC50 
values ranged between 100 M and 1 mM.   
 It is known that small molecules identified through large structural databases with high 
IC50 values can be non-specific aggregators, sequestering the enzyme to its surface preventing 
activity and causing partial denaturation [236, 237]. Aggregation-based inhibition can be 
reversed through the addition of non-ionic detergents such as Triton X-100. Therefore to assess 
the selectivity of our enzyme inhibitor, we re-assayed the dose-dependence with the addition of 
0.01% Triton X-100, which had no effect on the normal enzymatic activity of m-Ddh. The IC50 
values for 4, 5 and 6 showed no significant difference in activity (Table 5).  
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Table 5. Analysis of m-Ddh enzymatic inhibition with active compounds. 
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Evaluation of cellular inhibition against m-Ddh. To determine if the small-molecule inhibitors 
displayed antimicrobial activity, we assessed the minimum inhibitory concentration (MIC) using 
a standard broth microdilution assay. Compounds 4, 5 and 6 were tested for their ability to 
visually inhibit growth of P. gingivalis cells and Erm was used as a control. Compounds 4 and 5 
showed moderate antimicrobial activity with MICs of 250 M and 167 M, respectively (Table 
6). With an MIC over 2 mM, compound 6 was determined not to be appropriate for whole-cell 
growth inhibition. Testing of the minimum bactericidal concentration (MBC) following the MIC 
assay, showed only slight differences between the MBC and MIC value (ratio of less than 4:1) 
for compound 4 and 5. Compound 6 was not screened for bactericidal activity as the 
concentration higher than the MIC would have been affected by the solvent concentration. 
As a preliminary screen to link growth inhibition to our specific target, we first screened 
the compounds against P. intermedia, another Gram-negative oral pathogen that also possesses 
the target and S. sanguinis, a Gram-positive oral colonizer that does not. Comparison of the data 
did indicate select growth inhibition. P. intermedia showed increased sensitivity to compound 4 
but decreased sensitivity to 5. However, 4 and 5 had the greatest differences between S. 
sanguinis and P. gingivalis growth inhibition. Compound 4 showed 7× MIC of P. gingivalis and 
5 was more than double. Compound 6 didn’t show significant levels of inhibition similar to P. 
gingivalis and P. intermedia (Table 6). Previous studies show that supplementation of m-DAP 
into to the media of mutants lacking one or more of the enzyme within the m-DAP/lysine 
biosynthesis pathway can allow for growth and recovery [180, 183, 238]. Thus, to further link 
growth inhibition with m-Ddh inhibition, we re-assessed the MICs with the addition of the 
target’s essential product m-DAP. This had no effect on the growth inhibition for 5 or 6 in P. 
gingivalis, P. intermedia or S. sanguinis. However, compound 4 showed a slight increase in 
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  Table 6. Analysis of whole-cell inhibition with active inhibitors 
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sensitivity when 25 M of m-DAP was added to the assay for P. gingivalis and P. intermedia 
(Table 6).  
As MICs are static measurements, we wanted to next observe the kinetic effects the three 
active inhibitors had on the growth of P. gingivalis. Cells were exposed to the compounds and 
total viable cells were measured at different time intervals. At 5× MIC, compound 4 reduced the 
viable P. gingivalis cell count by 2 log10 CFU /ml within 6 h of exposure.  However, 5 rapidly 
reduced the cell count upon treatment. After 2 h of exposure there was a 5 log10 CFU/ml 
reduction, resulting in no viable cell count (Fig. 17). Cells exposed to 6 at the higher 
concentration treatments were affected by the DMSO solvent and could not be assessed.  
Phenotypic profiling linking target inhibition to growth effects were assessed by changes 
in the cellular morphology. P. gingivalis cells exposed to either compound 4 or 5 were examined 
by scanning electron micrograph (SEM). Compound 6 was left out of the analysis due to the high 
MIC concentration. Treated P. gingivalis showed an alteration of the cellular structure compared 
to the untreated cells (Fig. 18). Cells were visibly misshapen.   
SAR evaluation of compound 4 core scaffold. From our target-based screening assay, 
compound 4 displayed the most potent activity. Therefore, commercially available analogues 
with 70% -90% structural similarities identified through the ZINC database were purchased and 
screened for a preliminary evaluation of the core scaffold SAR. The structures and activities are 
listed in Table 7. The analogues differ at two substitution sites at both ends of the structure with 
IC50 ranging from 127 – 238 M. Removing the methoxy group from the R1 phenyl group of the  
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Figure 17. Time-kill analysis of compound treated P. gingivalis. 
P. gingivalis cells were treated with 5x the previously determined MIC for either Compound 4 (triangle) 
or Compound 5 (square) and bacterial cell counts were assessed at 0, 0.25, 0.5, 1, 2, 3, 4, 6 and 24 hours. 
The mean plus the standard deviation is shown for each time point from a minimum of n=3 independent 
experiments. For cell counts equal to 0 CFU/mL, 1 was used for the log transformation.  
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Figure 18. SEM analysis of compound treated P. gingivalis cells. 
(a) Untreated cells. (b) Compound 4 treated cells at 5x the previously determined MIC concentration. (c) 
Compound 5 treated cells at 5x the previously determined MIC concentration. 
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Table 7. SAR of compound 4 analogues. 
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original structure and replacing it with a methyl group resulted in the most potent inhibitor 
screened with a slight decrease in the IC50 (compound 4a, IC50 =127 M). This may be due to a 
decrease in size preventing a steric hinderance. However, adding electron withdrawing 3- or 4- 
carboxyl or electron donating 3-hydroxyl groups on the core R2 phenyl moiety, didn’t exhibit 
any significant effect on the activity. This was observed from the structures of compound 4a-4d 
suggesting that substitutions are tolerated around the ring within the binding site of these 
compounds. However, the addition of methyl groups to the 3- and 4- position on the R1 phenyl 
moiety for 4e resulted in an increase in the IC50 (IC50 = 238 M). Comparison with between 
compound 4a and 4e suggest that an additional moiety to the 3-position of the phenyl ring is less 
tolerable to the intermolecular interaction.  
Evaluation of inhibition mechanism. Based on our pharmacophore model and docking studies, 
our three active inhibitors share a similar binding pattern within the active site, competing with 
m-DAP. The intermolecular interactions are depicted in Figure 19. Hydrogen bond interactions 
are represented by dashed lines. The interactions are shown to follow the proposed 
pharmacophore models in that hydrogen bonding interactions between the sulfonamides are 
occurring with Arg183 and Thr173. Hydrophobic stacking interactions occur between the 
aromatic rings of the inhibitors and residues Phe148 and potential Trp123 of the active site. 
There may also be potential hydrogen bonding between the ligands’ carboxylic groups and 
residues Gly155 and Met154. In addition, for our model, the carboxylate groups form hydrogen 
bonds with the backbone amide of Ser153 and Met154. Compound 4 makes an additional 
hydrogen- bonding interaction with Tyr207 and - stacking interaction with Phe148, which 
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Figure 19. 3D analysis of binding model for active inhibitors. 
Optimal binding model for Compound 4 (a), Compound 5 (b) and Compound 6 (c) are shown above. Key 
residues are displayed as ball and sticks and colored corresponding to atom type. Residues labeled in the 
bottom middle figure correspond to all figures. Hydrogens were omitted for clarity. Potential hydrogen 
bonding interactions between m-Ddh residues and inhibitors are shown by yellow dashed lines.  
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Figure 20. Inhibition mechanism of active compounds in regards to substrate, m-DAP and co-
substrate, NADP+. 
(a) Compound 4 (b) Compound 5 and (c) Compound 6 inhibition mechanisms against m-DAP. (d) 
Compound 4 (e) Compound 5 and (f) Compound 6 inhibition mechanisms against NADP+. 
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may be one of the many reasons for its better activity. To verify this interaction, the method of 
inhibition was kinetically determined. The substrate m-DAP was varied over several 
concentrations of each inhibitor. The inhibition pattern for all three compounds was revealed to 
be non-competitive, as there was no change in the Km and a decrease in Vmax compared to the 
activity in the absence of the inhibitor (Fig. 20a-c). Due to structural similarities between the 
compound scaffolds and the co-substrate and the proximity of the two binding sites, we next 
examined the possibility that one of more of the inhibitors may be binding in the NADP+ binding 
site. This inhibition study showed an uncompetitive inhibition pattern as there was an increase in 
the Km and a decrease in Vmax compared to the enzymatic rate in the absence of the inhibitor 
(Fig. 20d-f).  
 
Discussion 
In this study, we evaluated the activity of compounds identified through a CBDD method. A 
two-step screening strategy was employed to assay m-Ddh specific inhibition and P. gingivalis 
growth inhibition. From 11 compounds purchased and screened in vitro, three showed target-
specific inhibition with IC50 values ranging from 100-300 M. Several other compounds showed 
slight activity in the higher millimolar range. The most potent compounds (4, 5 and 6) showed 
limited structural similarity. The core structure of compound 4 and 6 were both sulfonyl amino 
quinoxaline derivatives while 5 was a sulfonyl amino naphthalene derivative. However, all three 
possessed similar functional groups and were predicted to share basic pharmacophoric features. 
The three compounds possessed a sulfonamide core attached to large aromatic structures with 
carboxylate functional groups. The importance of the sulfonamide has literature precedence in 
the search for antimicrobials targeting lysine biosynthesis. Compounds structurally similar to our 
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hits that possessed sulfonamides and sulfones were identified as fairly good inhibitors of 
dihydrodipicolinate reductase, another enzyme in the lysine biosynthesis pathway [239, 240]. 
Based on docking studies, the sulfonamide groups were predicted to favorably interact with 
Arg183 and Thr173 forming hydrogen bonds, while the aromatic moieties would create 
hydrophobic interactions. From docking studies it appears the distance of the carboxylic groups 
may not allow for hydrogen bonds with residues at the other end of the binding pocket. However, 
based on other studies, m-Ddh exists in an open and closed conformation [218]. This would 
bring the residues surrounding the compounds within the distance necessary to form stronger 
hydrogen bonds. It should be noted that previous studies have reported more potent inhibitors 
against m-Ddh [209, 239, 241]. However, these compounds are typically small analogous 
structures, derived from the substrate m-DAP that possess few ‘drug-like’ features, making 
optimization difficult [239], and suggesting little hope for selectivity. Our compounds allow for 
the development of more active compounds, similar to the in silico screening against thymidylate 
synthase, an enzyme is essential for DNA replication, by DesJarlais et al. [242]. The initial 
computational study yielded several compounds with activity in the high micromolar range, but 
following further analysis and optimization resulted in an increase in potency as well as 
verification of the binding mode.  
In the pursuit of a preliminary SAR analysis, 5 analogues of the most active inhibitor 
(compound 4) scaffolds were screened. Through a small substitution, we identified one 
compound (4a) that showed a slight increase in activity and one compound with a decrease in 
activity (4e). Based on our predicted knowledge of the compound binding, comparison of the 
intermolecular interaction of 4a and 4e indicate, while the binding model appears similar, 
experimentally it appears the additional functional groups around the phenyl ring closer to 
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Trp123 and Phe148 within the binding pocket are not favored. On the other end, additional 
groups to the phenyl ring near Thr173 and Gly155 are tolerated. Screening of an analogue with a 
3-methyl addition at the R1 substitution and 3-carboxyl at the R2 substitution would allow for the 
direct comparison to 4a. This would allow us to determine if the methyl group in the para- 
position increases the potency and if the additional methyl group decreases potency. The addition 
of a hydroxyl group or a carboxylate in the 3- or 4-position showed no significant difference in 
activity. As this is a preliminary SAR study, screening analogues with increased structural 
diversity or fragment-based screening based on the deconstruction of the core scaffold will 
provide a more comprehensive analysis of the essential interactions.   
 Previous initial-velocity data [216] in m-Ddh show that the reaction proceeds through a 
sequential ordered ternary-binary mechanism with NADP+ binding first, followed by the 
substrate m-DAP. The product is then released, followed by NADPH. Our studies into the 
mechanism of inhibition show the inhibitory compounds to be non-competitive with respect to 
m-DAP, but uncompetitive with respect to NADP+. In concordance with the binding order, this 
would indicate that the compounds bind to either the Enzyme-NADP+ complex or the Enzyme-
NADPH complex, thus potentially preventing a necessary conformational change and/or 
reducing the affinity of m-DAP for the protein. This type of mechanism of inhibition could be 
beneficial for future therapeutics. Treatment with an optimized inhibitor competing with m-DAP, 
would result in the accumulation of the substrate within the cytosol or a regulation mechanism in 
order to meet the need of the cell. An increase in the localized substrate would then need to be 
balanced by high concentrations of the inhibitor. A non-competitive inhibitor, however would 
not be affected by the increased concentration of substrate compared to a competitive inhibitor, 
making it more effective at lower concentrations.   
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 One of the most difficult aspects of target-based drug discovery is identifying compounds 
that show effective whole-cell activity while maintaining the key pharmacokinetics. While the 
compounds identified showed potential against m-Ddh, they exhibited only slight antimicrobial 
activity in P. gingivalis. Nevertheless, the potential for antimicrobial activity should not be 
ignored as analogous structures and optimization of the scaffold could improve whole cell 
inhibition. Several reasons could contribute to the low observed MIC values. For one, bacterial 
inhibitors must be able to penetrate the cell membrane while maintaining enough soluble and 
free fractions to inhibit the target at sufficient concentrations. The compound also must avoid 
being expelled from the cell through efflux pumps. Another reason could be due to the 
sulfonamide group present on compounds 4, 5 and 6. Sulfonamides are well known 
antimicrobials that target folate biosynthesis, and bacterial cells may show a degree of drug 
resistance [239]. There is also the potential for non-specific inhibition or off-target interactions. 
This would result in what appears to be a variation in activity between whole-cell and target 
inhibition. This was observed for compound 5 which displayed a lower MIC than IC50. While a 
detailed structure-activity relationship for the antimicrobial properties cannot yet be determined 
from these studies, it may be speculated that the more favorable whole-cell activity seen in 
Compound 5 compared to compound 4 and 6 is due to lipophilicity. The relatively low lipophilic 
nature of compound 6 (cLogP = 1.70) compared to 5 (cLogP = 3.68) may have decreased 
permeability through the cellular membrane of P. gingivalis. While compound 4 displayed the 
more potent target-based screening, the high lipophilic nature (cLogP =5.26) may have had a 
significant effect on the solubility, reducing the efficacy during cell-based screening [243].  
However, we were able to show differential activity indicating specificity. Testing in P. 
gingivalis and P. intermedia, both of which possess the target, m-Dh showed a greater degree of 
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growth inhibition compared to S. sanguinis, which lacks the target. Compounds tested for S. 
sanguinis showed almost no antimicrobial activity (compound 4 and 6) or MICs more than 
double that of those seen in P. gingivalis (compound 5). Supplementing m-DAP into the growth 
media as a substrate competitor to the compounds did not correlate to an increase in MICs. 
While previous studies show that supplementation of m-DAP for E. coli and M. smegatis mutants 
restores growth in DAP auxotrophs [180, 238], it is not known whether P. gingivalis can 
specifically uptake and utilize m-DAP for its benefit. In addition if the compounds act in a non-
competitive or irreversible manner, addition of m-DAP would not necessarily compensate for the 
inhibitor activity. Analysis of the kinetic growth inhibition indicated the activity of these 
compounds are time and dose dependent, with higher concentrations and longer exposure times 
leading to an increased loss of cell viability. Compound 5 completely eliminated P. gingivalis 
cell viability after two hours of exposure at 5x the MIC concentration, while Compound 4 
maintained a low cell count after six hours of treatment. This is also consistent with the MBC 
being less than 4x the MIC as antimicrobials with MBC in close range of the MIC are typically 
classified as bactericidal.  
  In conclusion, we demonstrate the rationale for applying a focused biochemical 
screening with CBDD to identify inhibitors. Our results show that by utilizing a target screen we 
can select compounds which actively inhibit m-Ddh from P. gingivalis, identify the inhibition 
mechanisms and assess the SAR. Coupled with whole-cell screen we can identify compounds 
with antimicrobial properties and link the MoA. While the activities of these first generation 
compounds are somewhat weak, continued studies into the intermolecular binding interaction 
could help to discern which features are key, allowing for the improvement of novel inhibitors.  
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Conclusion 
The goal of this project was to introduce the beginnings of a model for antimicrobial drug 
discovery using the periodontal pathogen, P. gingivalis. Accordingly, we have successfully 
presented a thorough strategy. By understanding the three main biological functions for bacterial 
survival, we were able to create a network of pathways connected to the synthesis of essential 
metabolic components. As we demonstrated, this allowed for the accurate prediction of essential 
genes as potential antibacterial targets. Additionally, we believe this protocol allows for the 
comparison of alternative pathways and gene sets for species-selective targeting. Following the 
selection of a target, rational computer-based drug discovery (CBDD) was applied for the rapid 
and cost-effective identification of small-molecule compounds. We continued with our model to 
show that analysis of the protein structure and intermolecular interactions allowed for the 
utilization of a high-throughput virtual screen to select compounds with a higher probability of 
demonstrating target inhibition. Finally, by developing a simple and effective screening strategy 
to assess target and cell growth inhibition, we established that we could determine the in vitro 
activity of selected small-molecule compounds. Through this screening, not only are compounds 
with activity verified, but the mechanism of inhibition is determined and SAR studies can be 
started.  
The significance of our study should also be noted for our chosen model. First, we 
identified m-Ddh, an essential enzyme for P. gingivalis, as a potential pathogen-specific target 
within the oral cavity. The dual role of m-Ddh in protein and cell wall biosynthesis makes it an 
exceptional drug target, as it would inhibit two essential biological processes. Additionally, m-
Ddh is present within several other pathogenic colonizers, including P. intermedia, T. denticola 
and T. forsythia, while absent in the majority of early oral colonizers. Since m-Ddh is a unique 
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target found within a limited number of species, we theorize this would allow us to potentially 
develop novel narrow-spectrum therapy for the treatment of periodontal disease by specifically 
targeting key pathogens yet preserving the healthy microbiome. Second, to the best of our 
knowledge, this is the first computationally motivated target-based drug discovery for this 
periodontal pathogen. CBBD is a successful strategy, especially in systemic diseases [202]. By 
applying CBBD we were able to identify over 100 small molecule compounds with the potential 
of target-specific inhibition. Screening of the top-ranked, commercially available compounds, 
resulted in a 36% hit rate. Demonstrating that a CBDD can be applied to this bacterium, we hope 
this will drive new focus into drug therapies for oral diseases utilizing a rational approach. Last, 
P. gingivalis and periodontal disease can be used as the starting model for rational species 
selective drug discovery. As the human body is colonized by billions of microbial cells, it is 
highly unlikely a bacterial infection, especially a biofilm, would be isolated into a single species. 
Therefore, careful consideration of the effect therapeutic treatment has on the microbiome should 
be taken, bringing into play the justification for targeted therapies. We theorized periodontal 
disease and P. gingivalis would be a beneficial model as the oral microbiome is one of the most 
diverse sites on the body and P. gingivalis is widely recognized as one of the major contributors 
to periodontitis [32, 34, 70, 86, 244]. P. gingivalis can easily be cultured in the lab within a 
reasonable amount of time, allowing for in vitro testing. Additionally, periodontal disease has 
been extensively studied for years yielding suitable models for the disease, both in vitro and in 
vivo [245-247].  
Some challenges encountered during this study should be addressed as they may add in 
the future improvement of the process.  For one, it is important to verify that the target is 
essential in vivo and in vitro. Essential gene studies are usually preformed under laboratory, 
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nutrient-rich conditions. This does not always correspond to in vivo conditions where nutrients 
may be provided by the host or alternate pathways induced through stress factors. This is 
especially important for broad-spectrum targeting across multiple species. If possible, ex vivo 
models can be established that more closely mimic in vivo growth conditions and gene 
essentiality can be observed in various nutrient conditions. Subsequently, rational drug discovery 
assays must be designed to verify target inhibition during cell-based screening. The use of WT 
and mutant bacteria strains that overexpress and underexpress the target will not only identify 
compounds with antibacterial properties but select for those with target-specific inhibition. 
Alternatively, inducible antisense RNA could be used to control the expression level of the target 
and sensitivity to different inhibitor concentrations can be gauged. The compound database 
screened also needs careful consideration. Through studies by Lipinski et al., it was observed 
that these inhibitors generally follow certain traits (no more than 500 Da in size, five or fewer 
hydrogen bond donors, no more than 10 hydrogen bond acceptors and a logPo/w no greater than 
five), known as Lipinski’s rule of five [187, 188]. However, antimicrobials do not always follow 
this rule [97, 126]. Analysis of clinically approved antibiotics show that they are structurally 
more complex and larger in size. They also possess more hydrogen donors and acceptors and are 
more hydrophilic [97, 126]. Increased structural diversity in established chemical libraries or the 
construction of dedicated databases with compounds possessing antimicrobial properties would 
be beneficial. There has also been a resurgence in the search for natural compounds, similar to 
those identified during the ‘golden era’ of antibiotic research [97, 248]. Combining these 
compounds with a CBDD approach and other technical advances may bring new interest and 
success in this field of research.   
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 We anticipate several directions for future studies. We first intend to continue the 
evaluation of the MoA to link whole-cell activity to target inhibition. By placing m-Ddh under an 
inducible promoter we can regulate the expression and screen compounds for changes in whole-
cell growth inhibition. A more focused SAR study is also underway through the 
deconstruction/reconstruction of the three active compound inhibitors. The scaffold of the three 
active compounds will be systematically broken down into core functional groups. The basic 
structure of these compounds will then be re-evaluated through in silico and in vitro screening to 
assess the differences in activity and potency. The compound will then be reconstructed to 
include only the essential functional groups. Following an increase in target-based inhibition, the 
structure can be further optimized for increased whole-cell activity. We also plan to further 
evaluate the protein-compound binding. Select mutants will be made near the binding pocket of 
m-Ddh that do not have a significant impact on the catalytic efficiency. Compounds will then be 
re-screened against the mutants and inhibition will be measured to determine if the mutant 
affected compound binding compared to WT. We also screened a relatively small number of 
compounds from the results of our SBVS. Therefore, we plan to have a second round of 
screening from the remaining hits to increase our pool of active compound inhibitors.  
To conclude, we suggest that this method is an interdisciplinary approach whose 
application has the potential to extend beyond what has been shown here. Employing a 
combination of microbiologists, medicinal chemists and bioinformaticians we believe with time 
this approach can flourish. Using their knowledge in the necessary fields and taking the 
backbone of this project, we hope this can be applied to increasing deadly pathogens, such as M. 
tuberculosis, as an alternative method in antibacterial research.   
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Supplemental Table 1. Predicted putative essential genes in P. gingivalis strain W83. 
Functional 
category 
Pathway KEGG Pathway 
KEGG 
KO# 
GeneID Name Protein ID  
Cell envelope 
(cell 
membrane) 
Peptidoglycan 
biosynthesis 
Peptidoglycan 
biosynthesis 
K00075 PG1342 murB 
UDP-N-
acetylenolpyruvoylgluc
osamine reductase 
E 
K01924 PG0581 murC 
UDP-N-
acetylmuramate--L-
alanine ligase 
E 
K01925 PG0578 murD 
UDP-N-
acetylmuramoyl-L-
alanyl-D-glutamate 
synthetase 
E 
K01928 PG0576 murE 
Mur ligase family 
protein 
E 
K03340 PG0806 - 
Gfo/Idh/MocA family 
oxidoreductase 
E 
K01921 PG0729 ddl 
D-alanyl-alanine 
synthetase A 
E 
K01929 PG1106 murF 
D-Ala-D-Ala adding 
enzyme 
E 
K01000 PG0577 mraY 
phospho-N-
acetylmuramoyl-
pentapeptide-
transferase 
E 
K02563 PG0580 murG 
N-acetylglucosaminyl 
transferase 
E 
K05366 PG0794 pbp1a 
penicillin-binding 
protein 1A 
UA 
K03587 PG0575 - 
penicillin-binding 
protein 2 
E 
K00215 PG2002 dapB 
dihydrodipicolinate 
reductase 
E 
K00928 PG2189 lysC aspartate kinase E 
K00133 PG0571 asd 
aspartate-semialdehyde 
dehydrogenase 
E 
K01714 PG2052 dapA 
dihydrodipicolinate 
synthase 
E 
D-Glutamine and 
D-glutamate 
metabolism 
K01776 PG0705 murI glutamate racemase E 
D-Alanine 
metabolism 
K01775
K01929 
PG1097 alr 
putative bifunctional 
UDP-N-
acetylmuramoyl-
tripeptide:D-alanyl-D-
UA 
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alanine ligase/alanine 
racemase 
Terpenoid backbone 
biosynthesis 
(MEP/DOXP 
pathway) 
K01662 PG2217 dxs 
1-deoxy-D-xylulose-5-
phosphate synthase 
E 
K00099 PG1364 dxr 
1-deoxy-D-xylulose 5-
phosphate 
reductoisomerase 
E 
K00991 PG1434 ispD 
2-C-methyl-D-
erythritol 4-phosphate 
cytidylyltransferase 
E 
K00919 PG0935 ispE 
4-diphosphocytidyl-2-
C-methyl-D-erythritol 
kinase 
E 
K01770 PG0028 ispF 
2-C-methyl-D-
erythritol 2,4-
cyclodiphosphate 
synthase 
E 
K03526 PG0952 ispG 
4-hydroxy-3-
methylbut-2-en-1-yl 
diphosphate synthase 
E 
K03527 PG0604 ispH 
4-hydroxy-3-
methylbut-2-enyl 
diphosphate reductase 
UA 
Terpenoid backbone 
biosynthesis 
K00806 PG0190 uppS 
undecaprenyl 
pyrophosphate 
synthetase 
E 
 
Polysaccharide 
transporter 
- PG0117 - 
polysaccharide 
transport protein 
E 
Lipopolysaccha
ride 
biosynthesis 
Lipopolysaccharide 
biosynthesis 
K00677 PG0070 lpxA 
UDP-N-
acetylglucosamine 
acyltransferase 
E 
K02372 PG0071 lpxC 
bifunctional UDP-3-O-
[3-hydroxymyristoyl] 
N-acetylglucosamine 
deacetylase/(3R)-
hydroxymyristoyl-ACP 
dehydratase 
E 
K02536 PG0072 lpxD 
UDP-3-O-[3-
hydroxymyristoyl] 
glucosamine N-
acyltransferase 
E 
K00912 PG0638 lpxK 
tetraacyldisaccharide 
4'-kinase 
E 
K02527 PG1565 - 
3-deoxy-D-manno-
octulosonic-acid 
transferase 
E 
K02517 PG2222  acyltransferase E 
Fatty acid 
biosynthesis 
Pantothenate and 
CoA biosynthesis 
K00954 PG0369 coaD 
phosphopantetheine 
adenylyltransferase 
E 
K00859 PG0483 coaE dephospho-CoA kinase E 
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Biotin metabolism K03524 PG1601 birA 
biotin--acetyl-CoA-
carboxylase ligase 
E 
Fatty acid 
biosynthesis 
K02078 PG1765 acpP acyl carrier protein E 
K00648 PG2141 fabH 
3-oxoacyl-(acyl carrier 
protein) synthase III 
E 
K00645 PG0138 fabD 
malonyl-CoA:ACP 
transacylase, 
E 
K09458 PG1764 - 
3-oxoacyl-(acyl carrier 
protein) synthase II 
E 
K00059 PG1239 fabG 
3-ketoacyl-(acyl-
carrier-protein) 
reductase 
UA 
K02371 PG1416 fabK 
enoyl-acyl carrier 
protein(ACP) 
reductase, 
UA 
Glycerophosph
olipid / 
glycerolipid 
metabolism 
Glycolysis / 
Gluconeogenesis 
K01803 PG0623 tpiA 
triosephosphate 
isomerase 
E 
Glycerophospholipi
d 
metabolism/glycero
lipid metabolism 
K00057 PG1369 gpsA 
glycerol-3-phosphate 
dehydrogenase 
E 
K00980 PG2068 tagD 
glycerol-3-phosphate 
cytidylyltransferase 
E 
K00655 PG1249 plsC 
1-acyl-sn-glycerol-3-
phosphate 
acyltransferase, 
UA 
Glycerophospholipi
d metabolism 
K00981 PG0046 cdsA 
phosphatidate 
cytidylyltransferase, 
E 
Energy 
production 
Glycolysis 
Glycolysis / 
Gluconeogenesis 
K01810 PG1368 pgi 
glucose-6-phosphate 
isomerase 
E 
K01835 PG2010 pgm phophomannomutase UA 
K04041 PG0793 fbp 
fructose-1,6-
bisphosphatase 
E 
K01624 PG1755 fba 
fructose-bisphosphate 
aldolase 
E 
K00134 PG2124 gapA 
glyceraldehyde 3-
phosphate 
dehydrogenase 
E 
K00927 PG1677 pgk 
phosphoglycerate 
kinase 
E 
K01834 PG0130 gpmA 
2,3-
bisphosphoglycerate-
dependent 
phosphoglycerate 
mutase 
E 
K15634 PG1513 - 
phosphoribosyltransfera
se/phosphoglycerate 
mutase 
E 
K01689 PG1824 eno 
phosphopyruvate 
hydratase 
UA 
K01006 PG1017 ppdk 
pyruvate phosphate 
dikinase 
NE 
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K01610 PG1676 pckA 
phosphoenolpyruvate 
carboxykinase 
NE 
Pentose 
phosphate 
pathway 
Pentose phosphate 
pathway 
K00948 PG2097 prsA 
ribose-phosphate 
pyrophosphokinase 
E 
K01619 PG1996 deoC 
deoxyribose-phosphate 
aldolase 
UA 
NAD+/NADP+ 
biosynthesis 
Nicotinate and 
nicotinamide 
metabolism 
K00763 PG0057 pncB 
nicotinate 
phosphoribosyltransfera
se 
E 
K01950 PG0531 nadE NAD synthetase E 
K00858 PG0629 ppnK 
inorganic 
polyphosphate/ATP-
NAD kinase 
E 
Genetic 
Information 
inheritance 
Nucleotide 
biosynthesis 
Purine metabolism 
K00942 PG0512 gmk guanylate kinase E 
K00939 PG0791 adk adenylate kinase E 
Pyrimidine 
metabolism 
K09903 PG1902 pyrH uridylate kinase E 
K00384 PG1134 trxB thioredoxin reductase UA 
K00560 PG2060 thyA thymidylate synthase E 
K00945 PG0603 cmk cytidylate kinase E 
Purine 
metabolism/Pyrimid
ine metabolism 
K00525 PG1129 nrd 
ribonucleotide 
reductase 
NE 
Folate biosynthesis 
K01495 PG0625 folE GTP cyclohydrolase I E 
K00950 PG1541 folK 
2-amino-4-hydroxy-6-
hydroxymethyldihydro
pteridine 
pyrophosphokinase 
UA 
K01633 PG2091 folB 
dihydroneopterin 
aldolase 
E 
K00796 PG1589 folP 
dihydropteroate 
synthase 
E 
K01930 PG0463 folC 
dihydrofolate 
synthetase 
UA 
K00287 PG2061 folA dihydrofolate reductase E 
DNA repliction 
DNA replication 
(DNA polymerase 
III) 
K02343 PG1418 dnaX 
DNA polymerase III 
subunits gamma and tau 
E 
K02341 PG0932 - 
DNA polymerase III 
subunit delta' 
UA 
K02340 PG0949 - 
DNA polymerase III 
subunit delta 
E 
K02342 PG1852 - 
exonuclease (DNA 
polymerase III subunit 
epsilon) 
E 
K02342 PG0223 - 
exonuclease (DNA 
polymerase III subunit 
epsilon) 
NE 
K02337 PG0035 dnaE 
DNA polymerase III 
DnaE 
UA 
K02338 PG1853 dnaN 
DNA polymerase III 
subunit beta 
E 
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K02314 PG1242 dnaB 
replicative DNA 
helicase 
E 
K02316 PG1814 dnaG DNA primase E 
K03111 PG0271 ssb 
single-strand DNA-
binding protein 
E 
K01972 PG1253 ligA 
NAD-dependent DNA 
ligase LigA 
E 
K02335 PG1794 polA DNA polymerase I E 
DNA replication 
proteins (Initiation 
and re-initiation) 
K02313 PG0001 dnaA 
chromosomal 
replication initiation 
protein 
E 
K03530 PG0121 hup-1 
DNA-binding protein 
HU, 
UA 
K03530 PG1258 hup-2 
DNA-binding protein 
HU 
E 
DNA replication 
proteins (DNA 
topoisomerase) 
K02470 PG1702 gyrB DNA gyrase subunit B E 
K02469 PG1386 gyrA DNA gyrase subunit A E 
K03168 PG0754 topA DNA topoisomerase I E 
K02622 PG0368 parE 
DNA topoisomerase IV 
subunit B 
E 
K02621 PG1622 parC 
DNA topoisomerase IV 
subunit A 
E 
Homologous 
recombination 
(Holliday junction) 
K03551 PG0488 ruvB 
Holliday junction DNA 
helicase B 
E 
K07447 PG2202 - 
Holliday junction 
resolvase-like protein 
UA 
Transcription RNA polymerase 
K03043 PG0394 rpoB 
DNA-directed RNA 
polymerase subunit 
beta 
UA 
K03046 PG0395 rpoC 
DNA-directed RNA 
polymerase subunit 
beta' 
E 
K03086 PG0594 rpoD 
RNA polymerase sigma 
factor RpoD 
UA 
K03040 PG1911 rpoA 
DNA-directed RNA 
polymerase subunit 
alpha 
E 
Protein 
biosynthesis 
Ribosome 
K02863 PG0391 rplA 
50S ribosomal protein 
L1 
E 
K02886 PG1935 rplB 
50S ribosomal protein 
L2 
E 
K02906 PG1938 rplC 
50S ribosomal protein 
L3 
E 
K02926 PG1937 rplD 
50S ribosomal protein 
L4 
E 
K02931 PG1926 rplE 
50S ribosomal protein 
L5 
E 
K02933 PG1923 rplF 
50S ribosomal protein 
L6 
E 
K02935 PG0393 rplL 
50S ribosomal protein 
L7/L12 
E 
K02864 PG0392 rplJ 
50S ribosomal protein 
L10 
E 
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K02867 PG0390 rplK 
50S ribosomal protein 
L11 
E 
K02871 PG0375 rplM 
50S ribosomal protein 
L13 
E 
K02874 PG1928 rplN 
50S ribosomal protein 
L14 
E 
K02878 PG1931 rplP 
50S ribosomal protein 
L16 
E 
K02879 PG1910 rplQ 
50S ribosomal protein 
L17 
UA 
K02881 PG1922 rplR 
50S ribosomal protein 
L18 
E 
K02884 PG0037 rplS 
50S ribosomal protein 
L19 
UA 
K02887 PG0989 rplT 
50S ribosomal protein 
L20 
E 
K02890 PG1933 rplV 
50S ribosomal protein 
L22 
E 
K02892 PG1936 rplW 
50S ribosomal protein 
L23 
E 
K02899 PG0315 rpmA 
50S ribosomal protein 
L27 
E 
K02914 PG0656 rpmH 
50S ribosomal protein 
L34 
UA 
K02919 PG1915 rpmJ 
50S ribosomal protein 
L36 
E 
K02916 PG0990 rpmI 
50S ribosomal protein 
L35 
E 
K02895 PG1927 rplX 
50S ribosomal protein 
L24 
E 
K02897 PG0167 rplY 
50S ribosomal protein 
L25 
E 
K02876 PG1919 rplO 
50S ribosomal protein 
L15 
E 
K02907 PG1920 rpmD 
50S ribosomal protein 
L30 
E 
K02888 PG0314 rplU 
50S ribosomal protein 
L21 
E 
K02904 PG1930 rpmC 
50S ribosomal protein 
L29 
E 
K02945 PG1297 rpsA 
30S ribosomal protein 
S1 
UA 
K02967 PG0377 rpsB 
30S ribosomal protein 
S2 
E 
K02982 PG1932 rpsC 
30S ribosomal protein 
S3 
E 
K02986 PG1912 rpsD 
30S ribosomal protein 
S4 
E 
K02988 PG1921 rpsE 
30S ribosomal protein 
S5 
E 
K02990 PG0595 rpsF 
30S ribosomal protein 
S6 
E 
K02992 PG1941 rpsG 
30S ribosomal protein 
S7 
E 
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K02994 PG1924 rpsH 
30S ribosomal protein 
S8 
E 
K02946 PG1939 rpsJ 
30S ribosomal protein 
S10 
E 
K02948 PG1913 rpsK 
30S ribosomal protein 
S11 
E 
K02950 PG1942 rpsL 
30S ribosomal protein 
S12 
E 
K02954 PG1925 rpsN 
30S ribosomal protein 
S14 
E 
K02959 PG2117 rpsP 
30S ribosomal protein 
S16 
E 
K02961 PG1929 rpsQ 
30S ribosomal protein 
S17 
E 
K02963 PG0596 rpsR 
30S ribosomal protein 
S18 
E 
K02965 PG1934 rpsS 
30S ribosomal protein 
S19 
E 
K02952 PG1914 rpsM 
30S ribosomal protein 
S13 
E 
K02956 PG1758 rpsO 
30S ribosomal protein 
S15 
E 
K02996 PG0376 rpsI 
30S ribosomal protein 
S9 
E 
Aminoacyl-tRNA 
biosynthesis (tRNA 
synthetase) 
K01875 PG0316 serS seryl-tRNA synthetase E 
K01874 PG0170 metG 
methionyl-tRNA 
synthetase 
UA 
K04567 PG1370 lysS lysyl-tRNA synthetase E 
K01885 PG1566 gltX 
glutamyl-tRNA 
synthetase 
E 
K01886 PG1951 glnS 
glutaminyl-tRNA 
synthetase 
E 
K01883 PG1878 cysS 
cysteinyl-tRNA 
synthetase 
E 
K01887 PG0267 argS 
arginyl-tRNA 
synthetase 
E 
K01867 PG2085 trpS 
tryptophanyl-tRNA 
synthetase II 
E 
K01889 PG1771 pheS 
phenylalanyl-tRNA 
synthetase subunit 
alpha 
E 
K01890 PG0099 pheT 
phenylalanyl-tRNA 
synthetase subunit beta 
E 
K01870 PG1596 ileS 
isoleucyl-tRNA 
synthetase 
E 
K01881 PG0962 proS prolyl-tRNA synthetase E 
K01880 PG2165 glyS glycyl-tRNA synthetase E 
K01872 PG1246 alaS alanyl-tRNA synthetase E 
K01892 PG2062 hisS 
histidyl-tRNA 
synthetase 
E 
K01873 PG1132 valS valyl-tRNA synthetase UA 
K01868 PG0992 thrS 
threonyl-tRNA 
synthetase 
E 
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K01866 PG0263 tyrS 
tyrosyl-tRNA 
synthetase 
UA 
K01869 PG0796 leuS leucyl-tRNA synthetase E 
K01893 PG1121 asnC 
asparaginyl-tRNA 
synthetase 
UA 
K01876 PG0153 aspS 
aspartyl-tRNA 
synthetase 
E 
K00604 PG2023 fmt 
methionyl-tRNA 
formyltransferase 
E 
(tRNA processing) 
K01056 PG0166 pth 
peptidyl-tRNA 
hydrolase 
E 
K04075 PG2046 - 
hypothetical protein: 
tRNA(Ile)-lysidine 
synthase 
UA 
K00554 PG2035 trmD 
tRNA (guanine-N(1)-)-
methyltransferase 
E 
K00784 PG0739 elaC ribonuclease Z NE 
K03536 PG0201 rnpA 
ribonuclease P protein 
component, 
E 
K00566 PG0268 mnmA 
tRNA-specific 2-
thiouridylase MnmA 
E 
Translation factors 
(Initiation factor) 
K02518 PG1916 infA 
translation initiation 
factor IF-1 
E 
K02519 PG0255 infB 
translation initiation 
factor IF-2 
E 
K02520 PG0991 infC 
translation initiation 
factor IF-3 
E 
Translation factors 
(Elongation factors) 
K02358 PG0387 tuf elongation factor Tu E 
K02357 PG0378 tsf elongation factor Ts E 
K02355 PG1940 fusA elongation factor G E 
K02355 PG0933 fusA elongation factor G NE 
Translation factors 
(Release factors) 
K02835 PG0074 prfA 
peptide chain release 
factor 1 
E 
Translation factors 
(Recycling factors) 
K02838 PG1901 frr 
ribosome recycling 
factor 
NE 
Protein export 
K03070 PG0514 secA 
preprotein translocase 
subunit SecA 
E 
K12257 PG1762 secDF 
bifunctional preprotein 
translocase subunit 
SecD/SecF 
E 
K03106 PG1115 ffh 
SRP54, signal 
recognition particle 
GTPase protein, 
E 
K03076 PG1918 secY 
preprotein translocase 
subunit SecY 
E 
K03110 PG0151 ftsY 
SRPR, signal 
recognition particle-
docking protein, 
E 
Chaperones and 
folding catalysts 
(Protein folding) 
K04077 PG0520 groEL chaperonin GroEL E 
K04078 PG0521 groES co-chaperonin GroES E 
K03686 PG1776 dnaJ chaperone protein dnaJ, E 
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K04043 PG1208 dnaK 
molecular chaperone 
DnaK 
UA 
K00970 PG0801 - poly (A) polymerase UA 
(Protein maturation) 
K01265 PG1917 map 
methionine 
aminopeptidase 
E 
K01462 PG2201 def peptide deformylase E 
GTP-binding 
proteins 
GTP-binding 
proteins 
K03595 PG2142 era 
GTP-binding protein 
Era 
E 
K03979 PG0790 obgE GTPase ObgE E 
K03978 PG0346 engB GTPase EngB E 
K03977 PG2143 engA 
GTP-binding protein 
EngA 
E 
Cell division 
Chromosome 
partitioning proteins 
(cell division) 
K09811 PG1536 ftsX 
cell division protein 
FtsX, 
E 
K09812 PG2190 ftsE 
cell division protein 
FtsE, 
E 
K03588 PG0579 ftsW 
cell division protein 
FtsW, 
UA 
K03531 PG0584 ftsZ 
cell division protein 
FtsZ 
E 
K03590 PG0583 ftsA 
cell division protein 
FtsA 
E 
K03798 PG0047 ftsH 
cell division protein 
FtsH 
E 
K03589 PG0582 ftsQ 
cell division protein 
FtsQ 
UA 
K03569 PG1396 mreB 
rod shape determining 
protein MreB 
E 
K03570 PG1395 mreC 
rod shape determining 
protein MreC 
E 
Cofactors 
FMN/FAD 
biosynthesis 
Riboflavin 
metabolism 
K11753 PG0957 ribF 
riboflavin biosynthesis 
protein RibF 
UA 
SAM 
biosynthesis 
Cysteine and 
methionine 
metabolism 
K00789 PG1896 metK 
S-adenosylmethionine 
synthetase 
E 
E = Experimentally Essential 
NE = Experimentally Non-essential 
UA = Unaccounted in experimental data 
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Supplemental Figure 1. Example of transposon insertion for P. gingivalis strain W83. 
Top panel represents the transposon insertion pattern for an essential gene PG1959, rpmG 50S ribosomal 
protein L33. Bottom panel represents a transposon insertion pattern for a non-essential gene PG0392, rplL 
50S ribosomal protein L10. Highlighted blue bars depict the indicated gene sequence. Red arrows represent 
location and orientation of a single insertion. Each gene shows insertions for two technical repeats. Courtesy 
of Dr. Brian A. Klein. 
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Supplemental Figure 2. SDS PAGE and gel filtration analysis of purified m-Ddh from P. gingivalis. 
Samples were loaded on a 12.5% polyacrylamide SDS-PAGE gel and bands were detected by Coomassie G-
250 stain. (M) represents the protein standards marker (Bio-Rad) and (1-4) represent collected elution 
fractions during purification. Arrow points to the expected size of m-Ddh at approximately 32 kDa. A 
representative gel filtration chromatograph of purified m-Ddh in elution buffer ran on Superdex 75 column. 
The native molecular mass followed with the expected peak at approximately 66 kDa similar to the protein 
standard albumin. Standard 1 included cytochrome c and β-amylase, Standards 2 included carbonic 
anhydrase and alcohol dehydrogenase and Standards 3 included albumin.  
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